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 i 
Ágrip 
Framfarir í skurðlækningum og gjörgæslu hafa leitt til bættrar meðferðar 
sjúklinga sem þjást af hjarta- og æðasjúkdómum. Í dag eru opnar 
hjartaaðgerðir algengar á Vesturlöndum og útlit er fyrir að þeim muni fjölga á 
komandi áratugum, samfara auknum fjölda aldraðra. Sjúklingar sem gangast 
undir opnar hjartaaðgerðir eru oft með flókin heilsufarsvandamál sem eykur 
tíðni fylgikvilla. Á meðal algengustu fylgikvilla eftir opnar hjartaaðgerðir eru 
hjartsláttaróregla, einkum gáttatif, og blæðingar. Bráður nýrnaskaði (BNS) er 
einnig algengur fylgikvilli eftir hjartaaðgerðir og tengist verri horfum sjúklinga 
eftir aðgerð. Skortur á gögnum um grunnstarfsemi nýrna hefur þó verið galli á 
mörgum fyrri rannsóknum sem auk þess hafa oft á tíðum skoðað mjög 
sérhæfða sjúklingahópa. 
Árlega eru framkvæmdar um 250 opnar hjartaaðgerðir á Íslandi og eru um 
2/3 þeirra kransæðahjáveituaðgerðir. Markmið þessarar doktorsritgerðar var 
að meta tíðni og áhættuþætti BNS eftir hjartaaðgerðir á Íslandi en skort hefur 
á slíkar rannsóknir fram til þessa. Auk þess voru könnuð tengsl BNS og 
annarra fylgikvilla eftir opnar hjartaaðgerðir. Loks var samband BNS og 
langtíma skerðingar á nýrnastarfsemi rannsakað, þar með talið þörf á 
nýrnaskilunarmeðferð, sem og langtímalifun. Að lokum var sérstaklega lagt 
mat á hvaða áhrif bati á nýrnastarfsemi hefur á horfur sjúklinga sem hljóta 
BNS. 
Við rannsóknirnar var stuðst við gagnagrunna með ítarlegum upplýsingum 
um alla sjúklinga sem gengust undir hjartaaðgerð á Íslandi frá 2001-2015. 
Ber þar sérstaklega að nefna nákvæma skráningu á nýrnastarfsemi sjúklinga, 
bæði fyrir og eftir aðgerð, en þær upplýsingar eru forsenda til að geta lagt 
mat á tíðni og áhættuþætti BNS. 
Rannsóknirnar leiddu í ljós að tíðni BNS eftir hjartaaðgerðir er heldur lægri 
hér á landi samanborið við nágrannalönd okkar. Líktog aðrar rannsóknir hafa 
sýnt er BNS tengdur undirliggjandi ástandi sjúklinga og voru aldur, skerðing á 
nýrnastarfsemi fyrir aðgerð, hærri áhættustigun fyrir aðgerð, umfangsmeiri 
skurðaðgerð og hærri líkamsþyngdarstuðull sjálfstæðir áhættuþættir. 
Bráður nýrnaskaði tengdist verri horfum sjúklinga eftir aðgerð sem meðal 
annars endurspeglaðist í hærri tíðni ýmissa fylgikvilla. Gáttatif reyndist 
algengasti fylgikvillinn og greindist í nærri helmingi sjúklinga sem gengust 
ii 
undir kransæðahjáveitu- eða ósæðarlokuskiptaaðgerð á Landspítala. Auk 
þess kom í ljós að tíðni gáttatifs var marktækt aukin hjá sjúklingum sem fengu 
BNS. Eins og fyrir BNS, reyndust hærri aldur, umfang aðgerðar og hærri 
áhættustigun fyrir aðgerð vera sjálfstæðir áhættuþættir fyrir greiningu 
gáttatifis. 
Greining BNS tengdist einnig aukinni þörf á skammtíma 
nýrnaskilunarmeðferð og versnun á langtíma nýrnastarfsemi. Aukinheldur 
höfðu sjúklingar sem fengu BNS marktækt lakari lifun eftir aðgerð og reyndist 
langtímalifun í öfugu hlutfalli við alvarleika upphaflegs nýrnaskaða. Meirihluti 
sjúklinga virtist hinsvegar endurheimta nýrnastarfsemi eftir BNS í kjölfar 
aðgerðar. Bati á nýrnastarfsemi spáði ekki fyrir um eins árs lifun sjúklinga en 
hinsvegar lifðu sjúklingar sem náðu bata marktækt lengur en 
samanburðarhópur sem ekki náði bata.  
Með því að notast við yfirgripsmikla og nákvæma gagnagrunna, sem ná til 
heillar þjóðar, reyndist unnt að meta tíðni BNS og gáttatifs eftir opnar 
hjartaaðgerðir á Íslandi um leið og lifun og forspárþættir lifunar eftir þessar 
aðgerðir voru kannaðir. Flestir sjúklingar sem hlutu BNS endurheimtu 
nýrnastarfsemi og fáir hlutu endastigs nýrnabilun. Samt sem áður virðist BNS 
tengjast verri útkomu eftir hjartaaðgerð og ljóst er að úrræði skortir þegar 
greining BNS liggur fyrir. Snemmbúin greining BNS og kortlagning 
áhættuþátta á þó vonandi eftir að auka skilning okkar á BNS og hvernig 
fyrirbyggja má sjúkdóminn og að bæta horfur þessa sjúklingahóps.  
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Abstract 
In line with advances in surgery, perioperative care, and intensive care, the 
outcome in patients treated for cardiovascular disease has improved. Open-
heart surgery is common in most western countries and, in line with the 
general ageing of populations, the frequency of these procedures is expected 
to increase in the coming decades. Patients who undergo cardiac surgery 
often have complex medical problems that predispose them to a range of 
surgical complications. Among the most common postoperative 
complications are arrhythmias, most often atrial fibrillation, and bleeding. 
Acute kidney injury (AKI) is also a common and often serious 
complication―as well as being a strong risk factor for worse postoperative 
outcome and increased mortality after surgery. However, many previous 
studies have suffered from a lack of data on baseline kidney function before 
AKI as well as selective patient cohorts. 
Approximately 250 open-heart surgeries are performed annually in 
Iceland. However, there has been a lack of data on the incidence and risk 
factors for AKI following heart surgery. The aim of the studies in this thesis 
was to evaluate the incidence of AKI using internationally validated criteria. 
Furthermore, we wanted to examine the association between AKI and other 
postoperative complications, and also long-term outcome, mainly regarding 
kidney function and survival. In that context, we particularly examined the 
effect of recovery of renal function on long-term outcome. 
Data were gathered from comprehensive nationwide databases that 
contained detailed information on all patients who underwent heart surgery in 
Iceland from 2001 through 2015. Information on kidney function, both pre- 
and postoperatively, was recorded in a thorough manner, as it is a 
prerequisite for reliable evaluation of AKI. 
The studies showed that the incidence of AKI after cardiac surgery in 
Iceland was relatively low compared to neighboring countries. In line with 
previous studies, the preoperative condition of patients was shown to be 
associated with the incidence of AKI. Advanced age, reduced preoperative 
kidney function, higher preoperative risk assessment scores, a higher body 
mass index, and more complex surgery were found to be independent 
predictors of the development of AKI. 
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AKI was significantly associated with worse postoperative outcome, as 
reflected by higher rates of various postoperative complications when 
compared to patients with normal kidney function postoperatively. Atrial 
fibrillation, diagnosed in almost half of the patients, was the most common 
postoperative complication following surgical myocardial revascularization 
and aortic valve replacement in Iceland. Furthermore, the incidence of atrial 
fibrillation was higher in patients who sustained AKI than in those who did 
not. As in the case of AKI, the independent predictors of atrial fibrillation were 
advanced age, more complex surgery, and higher preoperative risk 
assessment scores.  
The diagnosis of AKI was found to be associated with an increased need 
for renal replacement therapy and worse long-term kidney function. Also, AKI 
patients had significantly higher postoperative mortality and worse long-term 
survival, with survival being inversely correlated to the severity of AKI. 
Importantly, the majority of patients recovered their renal function after AKI. 
Although renal recovery was not a significant predictor of one-year survival, it 
was found to be associated with more favorable long-term survival. 
By using extensive comprehensive nationwide databases, it was possible 
to determine the incidence of AKI after open-heart surgery in Iceland and to 
define risk factors. Most patients who sustained AKI recovered their renal 
function and the rate of progression to end-stage renal disease was low. 
Although AKI appears to be associated with a worse postoperative outcome 
in patients, early detection of AKI and gaining a better understanding of the 
risk factors remain important steps in reducing the morbidity and mortality of 
patients diagnosed with AKI. It is to be hoped that a better understanding of 
these factors will help to improve the long-term prognosis in this patient 
group, leading to increased rates of renal recovery and reduced costs of 
treatment. 
 
Key words:  
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1  Introduction 
Acute kidney injury (AKI) is a complex condition that is seen in diverse 
settings. The term covers a broad range of renal dysfunction, ranging from a 
slight decrease in kidney function to extensive renal injury. The aim of this 
thesis is to provide some insight into AKI after cardiac surgery, with emphasis 
on AKI following either coronary artery bypass grafting (CABG) surgery or 
aortic valve replacement (AVR). Normal anatomy and kidney function will be 
explained briefly before any further discussion on the mechanisms underlying 
AKI. Then the importance of baseline and postoperative kidney function will 
be examined and the effect of recovery of renal function following AKI 
assessed. Lastly, postoperative atrial fibrillation (POAF), the most common 
complication of open-heart surgery, and its relationship to AKI, will be 
examined. 
1.1 The kidneys 
The kidneys are a pair of bean-shaped, retroperitoneal organs that play an 
important role in various homeostatic mechanisms that are essential for 
survival (Figure 1). They serve in regulating fluid, pH, and electrolyte balance, 
filter and eliminate waste products of metabolism from the circulation, aid in 
the regulation of blood pressure via the renin-angiotensin-aldosterone 
system, and are important producers of hormones (Hall & Guyton, 2011; 
Wein et al., 2012).  
Figure 1. Anatomy of the kidney. 
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Each kidney normally has around 800,000 to 1.5 million nephrons, the 
kidney’s urine-producing functional units (Brenner, 2005). The nephron 
consists of an initial filtering component (the renal corpuscle) and an 
associated tubule. The renal corpuscle is made up of the glomerulus, a 
network of capillaries that receives blood from the afferent renal arteriole and 
is responsible for ultrafiltration of blood. The glomerulus is covered by a 
simple layer of squamous epithelium, called the Bowman’s capsule (Figure 2) 
(Wein et al., 2012). 
The kidneys usually weigh around 115-170 g in an adult human and make 
up only 1‒2% of the total body mass (Wein et al., 2012). However, every 
minute, between 20% and 25% of the total cardiac output passes through the 
kidneys and is filtered by them (Janson & Tischler, 2012). In the glomeruli, 
primary urine is produced at an approximate rate of 125 mL/min, amounting 
to roughly 180 L on a daily basis (Hall & Guyton, 2011). The tubuli serve to 
further modify the initial corpuscular filtrate before it progresses to the 
collecting system of the kidneys and is excreted from the body in the form of 
urine. 
Figure 2. The nephron.  
Glomerular filtration rate (GFR) is the term used to describe the rate of 
flow of filtered fluid through the kidney, and it is measured in mL/min. 
Glomerular filtration is a passive process governed by Starling forces that 
force fluid to filter along a pressure gradient. GFR depends on the filtration 
coefficient (KF) and the balance between factors driving and opposing 
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filtration (Figure 3) (Brenner, 2005). The main factor that drives filtration is the 
hydrostatic pressure inside the glomerular capillaries (Pc), whereas the 
hydrostatic pressure in the Bowman’s capsule (PB) and the mean colloid 
osmotic pressure of the glomerular capillaries (πc) oppose filtration (Guyton & 
Hall, 2006). Thus, GFR can be expressed by the following equation: 
GFR = KF × ((Pc − PB) − πc) 
Physiologically, GFR is primarily modified through changes in pressure 
inside the glomerular capillaries, which is in turn dependent on renal afferent 
arteriolar resistance (RA) and efferent arteriolar resistance (RE), as well as on 
systemic arterial pressure. It should, however, be noted that due to an 
autoregulation of GFR and the renal blood flow, the pressure in the afferent 
arterioles in the glomerulus remains constant over a wide range of systemic 
arterial pressure (Guyton & Hall, 2006). 
Figure 3. Factors governing glomerular filtration rate. Modified from http://pathway 
medicine.org/glomerular-filtration-rate. 
The condition that arises when the kidneys become incapable of 
maintaining GFR, and even of excreting nitrogenous waste, regulating 
electrolytes and intravascular volume, and in assisting in maintenance of the 
acid-base balance, is termed renal failure. Renal failure may be acute or 
chronic. Before any further explanation of the complex condition of renal 
failure, another key topic will be covered in the following sections, namely 
how renal function is assessed in clinical practice. 
1.2 Assessment of renal function 
Renal function can be estimated in several ways. For instance, urine output 
(diuresis), routinely monitored in patients in intensive care units (ICUs), is an 
indirect marker of renal function. Diuresis is, however, affected by several 
other mechanisms, e.g. the normal physiological response of increased 
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vasopressin secretion due to volume depletion and administration of 
diuretics. Diureses can therefore be an unreliable marker of renal function in 
the setting of AKI (Bellomo et al., 2004). 
The most accurate method of determining GFR, and thereby assessing 
renal function, is by performing repeated blood measurements of 
intravenously administered exogenous filtration markers (e.g. inulin, 
iothalamate, or iohexol), which, however, is economically and temporally 
impractical in clinical practice (Stevens & Levey, 2005, 2009).  
In the clinical setting, the most widely used method of estimation of GFR 
(eGFR) is measurement of serum levels of the endogenous filtration marker 
creatinine (SCr) (Brenner, 2005). Creatinine is an amino acid compound 
derived from the conversion of creatine to phosphocreatinine in skeletal 
muscle and subsequent metabolism in the liver. It is mainly excreted through 
glomerular filtration and secreted in an unchanged form (Miller, 2003; Taylor, 
1989). Measurement of SCr permits estimation of creatinine clearance, which 
in turn has an inverse correlation with GFR (Stevens & Levey, 2005). The 
normal range of eGFR is 90‒130 mL/min/1.73 m
2
, but around the fifth decade 
of life it begins to decrease (by approximately 10 mL/min/1.73 m
2
 per 
decade) (Brenner, 2005; Feehally et al., 2007). However, estimation of GFR 
by measurement of SCr has several important limitations (Bagshaw & 
Gibney, 2008; Shemesh et al., 1985; Waikar et al., 2009): 
i. Release of creatinine varies with age, sex, exercise, diet, and muscle 
mass.  
ii. Up to 10‒40% of creatinine is secreted by the proximal tubular cells 
of the kidneys, leading to overestimation of GFR, especially in states 
of renal dysfunction. 
iii. SCr values become abnormal only when there is a more than a 50% 
reduction in GFR. 
iv. SCr is a functional marker rather than an injury marker. Thus, it does 
not reflect kidney injury in the early stages, it may take up to 24 hours 
to rise following abrupt damage to the kidneys, and it has low 
predictive value regarding injury. Furthermore, critical illness itself 
may also cause large fluctuations in SCr due to factors such as 
deranged volume status and catabolic metabolism. 
The search for biomarkers that are more sensitive in the recognition of 
AKI is ongoing, but none are currently well enough established to replace 
creatinine as a biomarker of renal function (de Geus et al., 2012; Dedeoglu et 
al., 2013; Susantitaphong et al., 2013b). In the meantime, to overcome some 
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of the obstacles in using SCr and to increase the accuracy of GFR and 
creatine clearance estimations in clinical practice, equations adding 
demographic and clinical data to SCr values have been formulated. It should, 
however, be emphasized that all these equations are based on SCr, which, 
as already mentioned, has various limitations―especially in the AKI setting 
(Waikar et al., 2009). 
1.3 Estimation of GFR 
Despite efforts to correct for differences regarding age, sex, race, and body 
mass, it can be difficult to produce a single equation that can accurately 
predict creatine clearance and GFR in all clinical settings. The following three 
formulas have been in most extensive use: 
i. The Cockcroft-Gault formula was published in 1973, and provides 
estimated creatinine clearance values, which in turn provide an 
estimation of GFR. It is still widely used, but recommended drug 
doses are commonly based on Cockcroft-Gault values (Cockcroft & 
Gault, 1976). The equation was developed based on 249 males with 
steady-state SCr, and women were assigned an adjustment factor of 
0.85, based on a theoretically lower muscle mass (by 15%). Lean 
body weight is included in the numerator of the formula to adjust for 
muscle mass. That may, however, adversely affect the performance 
of the formula in patients where weight change is not a result of 
changes in muscle mass (e.g. pregnancy, obesity, and edematous 
states) (Coresh & Stevens, 2006). Furthermore, due to tubular 
secretion of creatinine, the formula will lead to overestimation of GFR 
(Botev et al., 2009). Since publication of the formula, SCr 
measurement has been standardized. However, samples from the 
original study are no longer available for measurement and there is 
no version of the equation with standardized creatinine values.  
ii. The Modification in Diet and Renal Disease (MDRD) formula for 
estimation of GFR was published in 1999, and has been extensively 
validated in populations between the ages of 18 and 70 with chronic 
kidney disease (CKD) (eGFR < 60 mL/min/1.73 m
2
) (Levey et al., 
1999). The equation has, however, been criticized for the fact that 
the study that it was based on was conducted on a population that 
was not representative of the general population―but rather a 
population with reduced kidney function (with a mean measured GFR 
of 40 mL/min/1.73 m
2
). The MDRD equation thus overestimates 
eGFR at values < 30 mL/min/1.73 m
2
, but underestimates eGFR at 
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values from 30 to 90 mL/min/1.73 m
2 
(Levey et al., 1999; Stevens et 
al., 2006). 
iii. The Chronic Kidney Disease-Epidemiology Collaboration (CKD-
EPI) formula for estimation of GFR was developed in 2009 and uses 
the same premises as the MDRD formula, but is more accurate in 
patients with eGFR > 60 mL/min/1.73 m
2
 (Levey et al., 2009). 
1.4 Acute renal failure 
Acute renal failure (ARF) involves an abrupt loss of kidney function (Webb & 
Dobb, 2007). It can have various causes, e.g. renal tissue damage, reduced 
renal blood flow, urinary tract obstruction, or exposure to nephrotoxins 
(Brenner, 2005). 
At the turn of the 21
st
 century, inter-study comparison of research on the 
subject of ARF suffered from a lack of consensus diagnostic criteria 
(Eknoyan, 2002). Indeed, at the time, over 35 different definitions of ARF 
were reported, leading to wide variations in reported ARF rates (Chertow et 
al., 1997; Kellum et al., 2002). In ARF, the decrease in renal function occurs 
abruptly, usually within hours or days, and results in imbalance in fluid and 
electrolyte states (Webb & Dobb, 2007). Many cases of ARF are reversible 
due to the kidney’s unique ability to recover from almost complete loss of 
function. So for a long time, ARF, in its less severe form was considered to 
be a relatively minor event with little clinical impact. However, there is 
mounting evidence to indicate that even a slight rise in SCr can negatively 
affect patient outcome, be it morbidity, short-term complications, or long-term 
mortality (Chertow et al., 1998; Lassnigg et al., 2004; Mangano et al., 1998). 
Changes in SCr could simply coincide with unmeasured variables that lead to 
increased mortality, but even after controlling for other clinical variables, a 
consistent linear relationship between reduced kidney function and worse 
outcome has been observed. Consequently, research has undergone much 
change in recent years―with the term AKI largely replacing the term ARF. 
1.5 Acute kidney injury 
Acute kidney injury is defined as a sudden and sustained decrease in kidney 
function that develops within seven days and leads to a rapid reduction in 
GFR (Webb & Dobb, 2007). Decreases in GFR stem from a decline in the 
number of nephrons, a decline in single nephron GFR, or both, and reflect 
various etiologies, including specific renal disease and extra-renal pathology 
(Brenner, 2005). This may result in extensive derangement of normal 
homeostasis, e.g. acid-base disturbances, electrolyte imbalance, retention of 
nitrogenous waste products, and fluid overload, and it has also been shown 
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to hasten progression of CKD and impair innate immunity (De Waele et al., 
2008; Rossaint et al., 2011; Thakar et al., 2003). 
As mentioned, AKI is a known complication in various clinical settings and 
it may develop as a consequence of complex interactions between an insult 
and subsequent activation of pro-inflammatory and coagulatory responses. 
However, AKI may occur with only minimal histological signs of tissue 
damage (Kosaka et al., 2016). 
AKI is a large and costly problem for patients and healthcare systems 
(Chertow et al., 2005). In a recent meta-analysis involving 312 studies and 
almost 50 million hospitalized patients worldwide, AKI was diagnosed in one 
in five adults and in one in three children (Susantitaphong et al., 2013a). The 
most common underlying causes for hospital-diagnosed AKI are sepsis and 
cardiac surgery (Susantitaphong et al., 2013a; Zakeri et al., 2005; Zarbock et 
al., 2014). One concern is the fact that studies have indicated that the 
incidence of AKI is rising, and the same holds true for incidence of AKI 
requiring dialysis (Hsu, 2010; Hsu et al., 2013). 
1.5.1  Defining AKI – the RIFLE, AKIN, and KDIGO criteria 
The use of varying definitions of AKI and the heterogeneity of different patient 
populations has led to large differences in reported AKI rates in previously 
published studies (Kaufman et al., 1991; Metcalfe et al., 2002). This in turn 
has made studies of the epidemiology and outcome of AKI unnecessarily 
complex (Gottlieb et al., 2002). In an effort to provide evidence-based 
guidelines, several interdisciplinary groups have proposed standardized 
criteria for the diagnoses and staging of AKI in the last decade. In the coming 
chapters, the three most frequently used criteria will be discussed further: the 
RIFLE, AKIN, and KDIGO criteria (see List of abbreviations). 
1.5.1.1 The RIFLE criteria 
The RIFLE criteria, shown in Table I, were published in 2004 (Bellomo et al., 
2004). The criteria are multi-level and consist of three graded levels of kidney 
injury (Risk, Injury, and Failure) and outcome measures (Loss of kidney 
function and End-stage kidney disease). They are based on a sudden 
increase in SCr and decrease in GFR or urine output (known or presumed to 
have developed over seven days or less) compared to baseline levels. Since 
they were published, various studies of different populations have shown the 
criteria to be useful in determining the incidence of AKI as well as being 
predictive of complications and perioperative mortality (Hoste et al., 2006; 
Kuitunen et al., 2006). 
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Table I: The RIFLE criteria for acute kidney injury (Bellomo et al., 2004).  
Stage SCr  criteria Urine output criteria 
Risk 1.5-fold increase in SCr or decrease in eGFR 
of > 25% from baseline 
< 0.5 mL/kg/h for > 6 h 
Injury 2-fold increase in SCr or decrease in eGFR 
of > 50% from baseline 
< 0.5 mL/kg/h for > 12 h 
Failure 3-fold increase in SCr, decrease in eGFR of 
> 75% from baseline, SCr ≥ 354 μmol/L or 
acute rise in SCr ≥ 44 μmol/L 
< 0.3 mL/kg/h for > 24 h 
or anuria for > 12 h 
Loss Complete loss of kidney function for > 4 weeks 
ESKD End-stage kidney disease (> 3 months) 
eGFR, estimated glomerular filtration rate; ESKD, end-stage kidney disease; SCr, 
serum creatinine. 
A major point of criticism of the RIFLE criteria is the requirement for 
baseline SCr values, which are often missing in the clinical setting. The 
criteria recommend assuming baseline GFR to be 75 mL/min/m
2
 when there 
is no history of CKD, and calculation of SCr by using the MDRD equation. 
However, studies have shown this to be too rough an approximation in many 
cases (Bagshaw et al., 2009; Pickering & Endre, 2010). 
1.5.1.2 The AKIN criteria 
The Acute Kidney Injury Network later modified the original RIFLE criteria, in 
an effort to increase both sensitivity and specificity (Table II) (Mehta et al., 
2007). The AKIN criteria differ from the RIFLE criteria mainly regarding the 
time component and the fact that not outcome measures are described. 
While the RIFLE criteria are defined as change within seven days, the AKIN 
criteria propose using 48 hours (Mehta et al., 2007). The AKIN criteria also 
include less severe kidney dysfunction in the diagnosis of AKI, and do not 
use GFR as a marker, as GFR has been shown to be unreliable in the setting 
of AKI. Lastly, the AKIN criteria propose that the diagnoses of AKI should 
only be made after optimization of fluid balance and exclusion of urinary tract 
obstructions. However, studies have failed to reliably show superior 
prognostic value of the AKIN criteria over the original RIFLE criteria 
(Englberger et al., 2011; Ostermann & Chang, 2011). 
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Table II: The AKIN criteria for acute kidney injury (Mehta et al., 2007). 
Stage SCr criteria Urine output criteria 
 1 Increase in SCr of ≥ 26.4 μmol/L in ≤ 48 h 
or 1.5- to 2-fold increase in baseline SCr  
< 0.5 mL/kg/h for > 6 h 
2 Increase in SCr to > 2- to 3-fold from 
baseline SCr 
< 0.5 mL/kg/h for > 12 h 
3 Increase in SCr to > 3-fold from baseline 
or baseline SCr ≥ 354 μmol/L with an 
acute increase of ≥ 44 μmol/L in ≤ 48 h 
< 0.3 mL/kg/h for > 24 h or 
anuria for > 12 h 
eGFR, glomerular filtration rate; SCr, serum creatinine. 
1.5.1.3 The KDIGO criteria 
Efforts have been made to further homogenize and improve the definition of 
AKI―with the KDIGO definition, combining the RIFLE and AKIN criteria, as a 
recent example (Table III) (Khwaja, 2012). The three classifications of AKI 
mentioned above have been compared in several studies, but no conclusive 
evidence of superiority of one system over the others has yet emerged 
(Bastin et al., 2013; Joannidis et al., 2009; Luo et al., 2014). 
Table III: The KDIGO criteria for acute kidney injury (Khwaja, 2012). 
Stage SCr criteria Urine output 
criteria 
1 SCr ≥ 1.5‒1.99 times baseline in ≤ 7 days or  ≥ 26.5 
μmol/L increase occuring in ≤ 48 h 
< 0.5 mL/kg/h 
for 6‒12 h 
2 SCr 2.0‒2.99 times baseline in ≤ 7 days < 0.5 mL/kg/h 
for ≥ 12 h 
3 SCr ≥ 3.0 times baseline in ≤ 7 days or 
SCr ≥ 354 μmol/L with either rise of ≥ 26.5 μmol/L 
in ≤ 48 h or SCr ≥ 1.5 times from baseline  ≤ 7 days 
or 
initiation of renal replacement therapy or 
in patients < 18 years a decrease in eGFR to < 35 
mL/min per 1.73 m
2
  
< 0.3 mL/kg/h 
for ≥ 24 h or 
anuria for ≥12 h 
eGFR, estimated glomerular filtration rate; h, hour; SCr, serum creatinine. 
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1.5.2  Ascertainment of baseline SCr 
Although standardized definitions of AKI, based on changes in SCr and urine 
output, have facilitated epidemiological studies, some controversy remains 
regarding the diagnosis of AKI. All the aforementioned criteria are based on 
relative deviance from baseline SCr, and they can be significantly affected by 
the choice of reference SCr. An important hurdle is choosing a suitable 
baseline SCr, i.e. one that accurately reflects kidney function in the steady 
state, prior to onset of AKI (Siew & Matheny, 2015). Studies have indicated 
that in patients for whom data on SCr is missing, the eGFR 75
 
approach, 
suggested in the RIFLE criteria, is likely to provide too rough an estimation of 
baseline kidney function in a study cohort (Bagshaw et al., 2009; Pickering & 
Endre, 2010). Knowledge of actual kidney function is preferable, and pre-
hospital SCr values may be useful in determining baseline SCr (Siew & 
Matheny, 2015). 
1.5.3  The pathophysiology and etiology of AKI 
To aid in diagnosis and management, the causes of AKI have been divided 
into three main categories (Brenner, 2005): 
i. Pre-renal: This accounts for approximately 55% of cases. It 
represents a physiological response to renal hypoperfusion (e.g. 
hypovolemia or low cardiac output) and―by definition―is reversible 
upon correction of renal blood flow, as no induction of ischemic injury 
to renal parenchyma has taken place. 
ii. Intrinsic: This comprises approximately 40% of cases, and it may be 
a complication of diverse diseases of the renal parenchyma. Most 
intrinsic injury is triggered by renal ischemia or nephrotoxins (such as 
radio-contrast or aminoglycosides). As such, intrinsic injury has been 
shown to go hand in hand with major cardiovascular surgery, trauma, 
hemorrhage, or sepsis. 
iii. Post-renal: This represents about 5% of cases and is caused by 
urinary tract obstruction, usually distally in the ureter or urethra. 
It has, however, been pointed out that this may be an oversimplification 
for underlying pathological mechanisms that frequently overlap, as evident in 
cases where hypoperfusion of renal tissue (pre-renal) may cause sufficient 
harm to lead to ischemic cellular injury and acute tubular necrosis (intrinsic) 
(Case et al., 2013). A schematic representation of postoperative AKI is 
shown in Figure 4. It highlights some of the complex interplay of various 
factors that affect the process. 
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Figure 4. A schematic representation of factors that contribute to AKI in the 
perioperative period (Brenner, 2005; Legrand & Payen, 2013). AKI, acute kidney 
injury; CO, cardiac output; P, pressure; PPV, positive pressure ventilation. 
1.5.4  Risk factors for AKI 
Risk factors for AKI can be divided into patient- or exposure-specific. 
Individual clinical factors known to increase a patient’s susceptibility include 
advanced age, diabetes mellitus, and congestive heart failure (CHF) (Long et 
al., 2016). As already mentioned, sepsis and cardiac surgery are the leading 
extrinsic causes of AKI (Susantitaphong et al., 2013a). Other reported risk 
factors include trauma, exposure to nephrotoxic drugs (e.g. radio-contrast 
and aminoglycosides), and burns (Bagshaw et al., 2008; Rewa & Bagshaw, 
2014). Lastly, pre-existing kidney disease is an established risk factor for the 
development of AKI, and the risk has been found to be proportional to the 
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respective stage of CKD (Hsu et al., 2008; Khosla et al., 2009). 
1.6 Postoperative AKI 
Postoperative AKI is believed to account for approximately 20‒50% of 
hospital-acquired AKI, and is a result of complex pathophysiological 
mechanisms (Carmichael & Carmichael, 2003). According to a large 
prospective multicenter study that examined ARF in almost 30,000 ICU 
patients, 41% of ARF cases were defined as postoperative (Uchino et al., 
2005). Cardiovascular surgical procedures were by far the most common 
surgical causes of postoperative AKI, comprising more than twice as many 
cases as the second most common surgical procedure, i.e. gastrointestinal 
surgery (56.4% vs. 27.8%). In contrast to cardiac surgery, considerably less 
emphasis has been placed on AKI following non-cardiac surgical procedures, 
perhaps due to a significantly lower incidence of AKI (Long et al., 2016). 
Nevertheless, there is some evidence that AKI may complicate up to one-
third of all major non-cardiac surgeries (Bihorac et al., 2009).. 
1.6.1  AKI following cardiac surgery 
Patients who undergo cardiac surgery are faced with a unique combination of 
possible renal stressors, related to both the surgery itself and, in some cases, 
the cardiopulmonary bypass (CPB) (Rosner & Okusa, 2006). Reported rates 
of AKI following open-heart surgery vary widely, depending on factors such 
as the patient population and the type and extensivness of surgery, but most 
are within the range of 15‒60% (Machado et al., 2009; Roh et al., 2012; 
Rosner & Okusa, 2006). The incidence of cardiac surgery-associated AKI 
(CS-AKI) is lowest after CABG, followed by valvular surgery, and it is highest 
after combined CABG and valvular procedures (Rosner et al., 2008). 
Multiple risk factors for AKI following cardiac surgery have been reported 
but among the most prominent are: emergency surgery, chronic kidney 
disease, and female gender (Bagshaw et al., 2008; Chertow et al., 1997; 
Mangano et al., 1998; Rosner & Okusa, 2006). Advanced age and diabetes 
have also been shown to be risk factors for AKI―a fact that has increasing 
implications considering constantly ageing patient populations and the 
growing incidence of diabetes (Wild et al., 2004). 
The pathophysiology of CS-AKI is complex and is believed to be 
multifactorial (Rosner & Okusa, 2006). It has, however, been proposed that 
the occurrence of CS-AKI may be explained by six different but 
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synergistically acting mechanisms: endogenous and exogenous toxins, 
metabolic mechanisms, neurohormonal activation, ischemia-reperfusion, 
oxidative stress, and inflammation (Bellomo et al., 2008).  
The latter two pathways are one of the reasons that lipid-lowering statins 
have been suggested as a possible prophylactic treatment for AKI, due to 
their anti-inflammatory and anti-oxidative properties (Morgan et al., 2009). 
This also holds true for another well-known complication of cardiac surgery, 
POAF (Liakopoulos et al., 2009). However, this possible pleiotropic effect of 
statin therapy has been disputed, and a recent randomized study examining 
the effects of treatment with rosuvastatin in patients undergoing cardiac 
surgery indicated no effect on rates of POAF. Also, rates of AKI were higher 
in the treatment group (Zheng et al., 2016). 
1.7 AKI in the ICU setting 
Most studies on the overall incidence of AKI in the ICU have found rates in 
the 40‒70% range, with mortality as high as 80% (Case et al., 2013; Hoste & 
Kellum, 2006). Furthermore, the incidence of AKI in the ICU setting has been 
on the rise worldwide (Bagshaw et al., 2007; Case et al., 2013). This trend 
appears not only to be due to the fact that older patients with more 
comorbidities and higher risk of AKI are being admitted to ICUs, as the 
incidence of AKI also seems to be on the rise in the less severely ill patients. 
However, studies have shown that acute physiology and chronic health 
evaluation (APACHE) scores and simplified acute physiology scores have not 
changed in line with changes in incidence (Bagshaw et al., 2007; Lameire et 
al., 2006). It has therefore been speculated that the increase in incidence of 
AKI may be due to the more rigorous diagnostic interventions in later years 
(Lameire et al., 2006). The highest incidence has been seen in patients with 
sepsis, but the incidence of AKI is generally lower in surgical patients than in 
medical patients in the ICU (Case et al., 2013). Even so, and reassuringly, 
recent studies have indicated that mortality in patients with AKI has 
decreased (Bagshaw et al., 2007; Waikar et al., 2006). This may stem from 
various factors such as the overall improvement in ICU treatment, a reduction 
in the use of nephrotoxic agents, and increased awareness of AKI (Waikar et 
al., 2006). 
1.8 Prevention and treatment of AKI 
Despite our improved knowledge of the pathophysiology of AKI, and 
advances in surgical techniques together with improved ICU management 
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(including dialysis therapies), effective therapeutic interventions for AKI have 
yet to emerge. Furthermore, randomized studies on various pharmacological 
agents and renal replacement therapy (RRT) have not shown any conclusive 
effect in reducing mortality (Bagshaw et al., 2013; Jo et al., 2007; Schneider 
et al., 2013). Emphasis is therefore placed on prevention. Although no single 
preventive measure reaches the highest levels of evidence, current 
recommendations are that one of the key targets for amelioration of AKI 
should be strict maintenance of hemodynamic stability (Prowle et al., 2014). 
Optimally, the goal should be to ensure that there is adequate renal perfusion 
and oxygen delivery to the kidneys, without fluid overload, as several studies 
have shown that overhydration increases the likelihood of adverse events 
and possibly contributes to AKI (Payen et al., 2008; Prowle et al., 2014; Stein 
et al., 2012). What is more, restrictive fluid management has been associated 
with reduced incidence of intra-abdominal hypertension (IAH), a well-defined 
risk factor for the development of postoperative AKI, especially following 
abdominal surgery (Dalfino et al., 2008).  
1.8.1 Renal replacement therapy 
When preventive measures fail and patients progress to end-stage renal 
disease (ESRD), RRT ensues. RRT may be indicated in patients with 
symptomatic CKD (e.g. electrolyte disturbances) (Lameire & Van Biesen, 
2010) or in patients with AKI (Ronco et al., 2015). In AKI, the most common 
indications are acidemia, electrolyte abnormalities, fluid overload that is 
unresponsive to diuretic treatment, complications of uremia, and―in rare 
cases―intoxication with dialyzable substances (Ronco et al., 2015). 
RRT includes conventional dialysis (both hemodialysis and peritoneal 
dialysis), hemofiltration and hemodiafiltration, and also kidney transplantation 
(Ronco et al., 2015). The first three treatment modalities take on the blood 
filtration role of the kidneys, but they lack other aspects of kidney function 
and are not curative (de Francisco & Pinera, 2006). They can be performed 
using arteriovenous or venovenous modes, either in a continuous manner 
(so-called continuous renal replacement therapy (CRRT)) or intermittently 
(Ronco et al., 2015) (Figure 5). In the ICU setting, patients are often selected 
for CRRT rather than intermittent hemodialysis, as they have lower MAP and 
are deemed too hemodynamically unstable to tolerate intermittent dialysis 
(Ronco et al., 2015). 
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Figure 5. A schematic overview of extracorporeal hemodialysis.  
1.9 Recovery of renal function 
There are more and more studies examining how patients who survive critical 
illness fare later on (Goldstein, 2014; Palevsky et al., 2005). An estimated 8‒
22% of critically ill patients suffer an AKI episode from which they fail to 
completely recover, which may even necessitate ongoing intermittant renal 
dialysis after discharge (Bell et al., 2007; Uchino et al., 2005). 
Animal studies have indicated that there is a causal relationship between 
AKI and CKD (Basile et al., 2001). Furthermore, a growing number of studies 
in humans also point to an association between AKI and progression of―or 
to―CKD (Amdur et al., 2009; Hsu et al., 2009; Ishani et al., 2011; Waikar & 
Winkelmayer, 2009). Following AKI, incomplete regeneration of the 
tubulointerstitial epithelium, characterized by fibrosis and persistent 
inflammation, may occur and correlate with loss of kidney function. However, 
the condition may remain subclinical for prolonged periods (Gueler et al., 
2004). 
Importantly, several studies on the long-term effect of AKI have suggested 
that early recovery of kidney function may be associated with better clinical 
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outcome after AKI (National Kidney, 2012; Rosner & Okusa, 2006). 
Furthermore, recovery of renal function following AKI has been shown to be 
an independent determinant of morbidity and mortality in patients (Bagshaw, 
2006; Pannu et al., 2013; Swaminathan et al., 2010). Factors that affect the 
long-term prognosis after AKI are not completely understood, but the process 
leading to development of CKD may be at least partially modifiable, e.g. by 
tighter regulation of blood pressure and diabetes (Murugan & Kellum, 2011).  
No agreed-upon criteria exist for the definition of recovery of renal function 
following an episode of AKI, making comparison of studies on the subject 
cumbersome. The majority of previously employed definitions fall into one of 
three categories: 
i. Freedom from dialysis (Bagshaw et al., 2005; Schiffl & Fischer, 
2008). 
ii. Absolute cut-off values of follow-up eGFR (Cantarovich et al., 2004; 
Macedo et al., 2012). 
iii. Relative changes in SCr or eGFR (Macedo et al., 2008; Pannu et al., 
2013). 
These definitions of renal recovery (RenR) vary widely, are based on 
functional improvement, and do not take into consideration the complex 
structural effect of acute injury on the renal tissue (Srisawat et al., 2010). This 
is an important point, as complete functional RenR may be noted even in the 
setting of residual structural damage, which in turn can have implications for 
progression to CKD (Gueler et al., 2004; Hsu et al., 2009). Furthermore, 
current definitions of RenR lack a relationship with the time course of 
recovery of renal function, and insufficiently define optimal length of follow-up 
of patients’ renal function following AKI. The RIFLE criteria propose a cut-off 
of 3 months after AKI prior to diagnosis of CKD in patients who do not have 
recovered renal function (Bellomo et al., 2004). However, some studies have 
revealed that the RenR process may go on for up to 18 months (Macedo et 
al., 2012). 
RenR, defined as liberation from dialysis, only covers those with the most 
severe forms of AKI. However, milder forms of AKI have also been shown to 
affect morbidity and mortality (Zakeri et al., 2005). Thus, definitions have 
emerged that outline absolute and relative changes in eGFR and SCr. 
However, a disadvantage of basing definitions of RenR on SCr and/or eGFR 
is the non-linear relationship between SCr and GFR (Figure 6). Another 
problem with definitions based on SCr might also be the confounding factor 
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of decreased muscle mass during severe illness (Srisawat et al., 2010). In 
addition, cut-off levels for criteria of renal recovery may in fact be over 
baseline in patients with advanced CKD, limiting the usefulness of the 
definition in that patient group (Macedo et al., 2012). On the other hand, the 
disadvantage of basing definitions of RenR on relative changes in SCr or 
eGFR is the dependency on availability of baseline SCr. 
Figure 6. The relationship of the estimated glomerular filtration rate (eGFR) to serum 
creatinine (SCr). The graph shows how a substantial decline in eGFR only leads to 
slight elevations in SCr on the flat part of the curve, meaning that a substantial 
decrease in eGFR may lead to a very subtle increase in SCr. However, on the steep 
part of the curve a very slight decrease in eGFR leads to a significant increase in SCr 
(Damman et al., 2012). 
The Acute Dialysis Quality Initiative (ADQI) Group sought to provide a 
consensus definition of AKI recovery, and suggested that complete RenR 
should be defined as a return of SCr to below the definition of RIFLE-R, or 
within 50% of baseline SCr. Furthermore, partial RenR was defined as 
freedom from RRT, but not to within 50% of baseline SCr (Bellomo et al., 
2004).  
A 2008 study with 5-year follow-up provided important insight into the 
course of AKI after critical illness. In the study, only 57% achieved full renal 
recovery (defined as eGFR within 10% of baseline) before hospital discharge 
(Schiffl & Fischer, 2008). The study also confirmed the poorer survival of 
patients diagnosed with AKI, even during long-term follow-up. This was most 
evident in patients with more extensive comorbidities and in those who did 
not achieve full recovery of kidney function. Furthermore, the study showed 
that if patients failed to reach normal renal function 6‒12 months after the 
index insult, no further improvement could be expected. Importantly, around 
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10% of the group that had only partially recovered renal function had a further 
decline in renal function during subsequent long-term follow-up. Lastly, the 
study highlighted that a further kidney insult in a patient recovering from AKI 
leads to a reduced likelihood of complete RenR (Schiffl & Fischer, 2008). 
Similarly, other studies have shown that more than one episode of AKI is an 
independent predictor of poorer survival (Guerin et al., 2000). This further 
drives home the message of the importance of scrupulous follow-up in this 
patient population, both during hospitalization and after discharge. 
Research on factors that affect RenR is in progress. Loss of 
autoregulation of renal blood flow and hypotension have been singled out as 
key factors in delayed RenR (Conger & Hammond, 1992). Fluid overload has 
also been shown to negatively affect renal recovery (Bouchard et al., 2009; 
Heung et al., 2012). Furthermore, it has been shown that the degree of 
recovery from AKI requiring dialysis is associated with the initial dialysis 
modality used (Sun et al., 2014). This is in line with the results of several 
other studies, with higher rates of RenR in patients treated with CRRT as 
compared to intermittent hemodialysis (Bell et al., 2007; Lin et al., 2009; 
Uchino et al., 2007). However, the effect of factors such as inflammation and 
oxygen delivery to the kidneys on renal recovery has yet to be fully 
determined (Srisawat et al., 2010). 
1.10 Chronic kidney disease 
During the acute phase of kidney injury, mechanisms such as hyperfiltration 
and hypertrophy may aid in ensuring the kidney‘s ability to secrete waste 
products. In the long run, however, they are believed to factor in as causes of 
progressive renal dysfunction due to propagation of increased glomerular 
capillary pressures, ultimately leading to glomerulosclerosis, destruction of 
renal parenchyma, and CKD (Helal et al., 2012; Wald et al., 2009). Whatever 
the underlying cause of CKD, patients usually experience progressive kidney 
dysfunction when the loss of functional nephrons reaches a certain threshold, 
as irreversible sclerosis occurs in the remaining, strained functional units of 
the kidneys (Hsu et al., 2009). Subsequently, the rate of progression depends 
on factors such as age, underlying etiology, and successful treatment of 
exacerbating factors (Gullion et al., 2006). There are many components that 
may exacerbate the process, i.e. systemic hypertension, hyperlipidemia, 
obesity, nephrotoxic substances (e.g. non-steroidal anti-inflammatory drugs, 
and various antibiotics), sub-optimally treated diabetes mellitus (DM), and 
smoking (Bash et al., 2009; Brenner, 2005; Chang et al., 2016; Thakar et al., 
2011). In a recent study, a validated risk calculator was reported, which is 
applicable to adult populations and based upon routine laboratory tests and 
baseline characteristics. The study showed that lower eGFR, albuminuria, 
young age, and male sex were indicative of higher risk of progression to end-
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stage kidney disease, the final stage of CKD. Furthermore, the results 
suggested that lower albumin, calcium, and bicarbonate levels and higher 
phosphate levels were predictive of elevated risk of disease progression 
(Tangri et al., 2011). 
However, the term CKD covers a wide range of kidney dysfunction, and in 
2002 the National Kidney Foundation’s Kidney Disease Outcome Quality 
Initiative (KDOQI) presented guidelines for classification of CKD ("KDOQI 
Clinical Practice Guideline for Diabetes and CKD: 2012 Update," 2012). They 
defined CKD as deranged kidney function and albuminuria with or without a 
decreased GFR, persisting for over three months. Furthermore, they divided 
CKD into stages based on the degree of the decrease in GFR (Table IV).  
Table IV: The KDOQI classification of chronic kidney disease ("KDOQI Clinical 
Practice Guideline for Diabetes and CKD: 2012 Update," 2012). 
Stage GFR Description 
1 ≥ 90 Kidney damage (albuminuria) with normal GFR 
2 60‒89 Kidney damage (albuminuria) with mild reduction of GFR 
3 30‒59 Moderate reduction of GFR 
4 15‒20 Severe reduction of GFR 
5 < 15 Kidney failure 
GFR, glomerular filtration rate. 
Importantly, studies have consistently shown a relationship between CKD 
and the development of vascular disease, be it coronary artery disease or 
peripheral vascular disease (Coresh et al., 2003; Gullion et al., 2006). Rates 
of hospitalization in patients with CKD are elevated compared to the general 
population, especially due to infections and cardiovascular diseases (Bash et 
al., 2009; Foley et al., 2005). Furthermore, all-cause mortality rates increase 
as kidney function decreases and mortality rates are up to six times higher in 
patients with stage-5 CKD compared to the general population (Go et al., 
2004). Interestingly, the leading cause of death in this group of patients is 
cardiovascular disease (CVD) (Neovius et al., 2014; Perazella & Khan, 2006; 
Tonelli et al., 2006). 
1.11 Cardiorenal syndrome 
The heart and kidneys cooperate in maintaining hemodynamic stability and 
organ perfusion, and are connected through interdependent relationships, 
e.g. neuronal and hormonal control (Brenner, 2005). A number of 
bidirectional interactions exist between the heart and kidney functions e.g. 
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regulation of electrolytes and fluid status (Ronco et al., 2008). The term 
cardiorenal syndrome (CRS) has been used to define the relationship in 
cases of dysfunction as: “a disorder of the heart and kidneys whereby acute 
or chronic dysfunction in one organ may induce acute or chronic dysfunction 
in the other” (Ronco & Ronco, 2012). CRS has been divided into five types 
(Ronco & Ronco, 2012) (Table V).  
Table V: Cardiorenal syndrome. 
Type Initial 
dysfunction 
Result Example 
1 Acute heart 
dysfunction 
Acute kidney injury or dysfunction Cardiogenic shock, 
acute decompensated 
heart failure 
2 Chronic heart 
dysfunction 
Progressive kidney dysfunction Chronic heart failure 
3 Acute kidney 
dysfunction 
Acute cardiac dysfunction (e.g. 
arrhythmia or heart failure) 
Acute kidney injury 
4 Chronic kidney 
disease 
Cardiac dysfunction or 
hypertrophy and/or higher risk of 
adverse cardiovascular events 
Chronic glomerular 
disease 
5 Systemic 
condition 
Heart and kidney dysfunction Diabetes mellitus, 
sepsis, hypertension 
It has since been argued that this might be too simplistic a definition, but 
the consensus remains that a pathophysiological condition may occur in 
which the combination of heart and kidney dysfunction can amplify organ 
dysfunction through induction of pathological mechanisms affecting both 
organ systems (Braam et al., 2014). In line with this are studies showing 
increased risk of major cardiovascular events in patients who experience 
postoperative AKI, especially in the setting of pre-existing heart or kidney 
dysfunction (Hansen et al., 2015; Ryden et al., 2014).  
1.12 Cardiovascular disease 
CVD is the sole leading cause of death globally (Laslett et al., 2012; Mortality 
& Causes of Death, 2015). Furthermore, although age-standardized mortality 
rates for CVD fell by 22% from 1990 to 2013, the total number of deaths 
attributed to CVD are expected to rise from the current 17.3 million to 23.6 
million in 2030, mainly due to ageing of the world population (Laslett et al., 
2012; Mortality & Causes of Death, 2015). However, in the past few years 
and decades, advances have been made in the treatment of CVD that range  
from public health measures to reduce the incidence of known risk factors 
(e.g. smoking and hypertension), medical treatments such as the use of 
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statins, percutaneous coronary intervention (PCI), and―not least―advances 
in surgical procedures.  
Generally, heart surgery is performed using CPB and the heart is arrested 
with potassium-rich cardioplegia. This allows the procedure to be performed 
on an empty and motionless heart. Then, during the operation, the CPB 
technique uses an extracorporeal circuit to filter and oxygenate blood before 
it is re-circulated into the systemic circulation (Figure 7) (Machin & Allsager, 
2006). 
Figure 7. Cardiothoracic surgery performed at Landspitali University Hospital. In the 
surgical wound are circuits of the cardiopulmonary bypass, emptying the heart of 
desaturated blood, circulating and oxygenating it extracorporally before re-circulation 
of it to the patient. Photograph courtesy of Ragnar Th. Sigurdsson. 
The first open-heart operation using CPB was performed in 1953 (Stoney, 
2009). Since then, advances in surgical techniques, anesthesiology and CBP 
technique, perioperative care, and ICU treatment have led to an era in which 
increasingly complicated cardiac procedures can be conducted. Ever older 
patients with more comorbidities are undergoing cardiac surgery (Horan et 
al., 2006), and the list of possible perioperative complications is extensive 
and includes death, bleeding, infections, and stroke. However, among the 
most common complications are heart arrhythmias, most often POAF, and 
AKI (Glance et al., 2007; Sigurjonsson et al., 2012). 
Coronary artery revascularization, first performed in 1960, is now one of 
the most commonly conducted open-heart surgeries, although the number of 
surgeries performed has decreased following advances in the field of PCI 
(Hannan et al., 2005). However, the large randomized SYNTAX trial, 
comparing PCI and CABG in patients with advanced CAD, showed that one-
year rates of major adverse cardiac and cerebrovascular events were 5.4% 
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lower in surgical patients (12.4% vs. 17.8%, p = 0.002) (Serruys et al., 2009). 
In line with these results and those from further studies on the subject, CABG 
remains the standard of care for three-vessel or left main stem coronary 
disease (Mohr et al., 2013; So, 2002) Other indications supporting myocardial 
revascularization surgery include debilitating angina, concomitant diabetes 
(Farkouh et al., 2012), occlusions not reachable by PCI, left main stem 
stenosis, poor left ventricular function (but with viable myocardium), ongoing 
ischemia in the setting of a non-ST-segment elevation myocardial infarction 
unresponsive to medical therapy, and total occlusion of a coronary artery 
(Task Force et al., 2013). Emergency surgery may also be performed in the 
setting of an ST-segment elevation myocardial infarction where PCI is 
impossible or has failed (Hillis et al., 2011). 
Myocardial revascularization surgery is generally performed with the help 
of CPB. However, CABG can also be performed on a beating heart (off-
pump, OPCAB), thereby circumventing the need for CPB and associated 
complications such as disturbances in the fibrinolytic system, activation of the 
systemic inflammatory response, non-pulsatile blood flow, and hypotension 
(Machin & Allsager, 2006; Sniecinski & Chandler, 2011). Since the advent of 
OPCAB surgery, several studies have sought to compare the off- and on-
pump techniques. Initial non-randomized studies indicated that the rates of 
various complications were lower following OPCAB (Gold et al., 2004). 
However, the largest randomized studies comparing OPCAB and 
conventional CABG, the ROOBY and CORONARY studies, have failed to 
show a significant change with regard to the incidence of AKI, POAF, stroke, 
myocardial infarction (MI), or perioperative death―further highlighting the 
complex association between CPB and AKI (Lamy et al., 2012; Lamy et al., 
2013; Shroyer et al., 2009). 
After CABG, AVR is the second most common open-heart procedure in 
most western countries ("Annual report SWEDEHEART 2012," 2014). AVR is 
most often conducted in patients with aortic stenosis (AS), usually secondary 
to degeneration of a tricuspid valve or calcification of a congenital bicuspid 
aortic valve. AS increases with age (Rajamannan et al., 2011) and its 
incidence has been reported to be 0.2% in patients aged between 50 and 59, 
1.3% in those between 60 and 69 years, 3.9% in those between 70 and 79 
years, and 9.8% in the age group 80‒89 years (Eveborn et al., 2013). By 
convention, AVR is conducted via a sternotomy using CPB and the diseased 
valve is replaced by a biological or mechanical prosthesis (Figure 8). 
Biological aortic valves may also be inserted using percutaneous techniques 
via femoral arteries, or with minimally invasive techniques through the apex 
of the left ventricle, which is called transcatheter aortic valve insertion (TAVI). 
Once in place, the prosthetic valve is expanded, pushing the leaflets of the 
old valve out of the way and taking their place (Dworakowski et al., 2010). 
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Both TAVI and AVR, and especially AVR, are considered to be effective 
therapies for severe AS, but the procedures have different complication 
profiles. In general, TAVI patients are at greater risk of postoperative 
paravalvular leakage, aortic regurgitation, and major vascular events, 
whereas surgical AVR patients are at greater risk of major bleeding, AKI, and 
new-onset POAF (Kodali et al., 2012; Mack et al., 2015; Thyregod et al., 
2015). 
Figure 8. Aortic valve surgery. The prosthetic valve is being sewn in place after 
removal of the diseased native valve. Photograph courtesy of Ragnar Th. Sigurdsson. 
1.13 Postoperative atrial fibrillation following cardiac 
surgery 
Arrhythmia is one of the most common complications of cardiac surgery and 
may negatively affect morbidity, length of hospital stay, and 30-day mortality 
(Almassi et al., 1997; Villareal et al., 2004). In the postoperative period,  
POAF is the most common arrhythmia, with the majority of studies reporting 
rates of 20‒40% following CABG, 40‒50% after valvular surgery, and up to 
60% following combined valvular and CABG surgery (Echahidi et al., 2008; 
Kowey et al., 2001; Maisel et al., 2001). POAF may present with obvious 
clinical symptoms such as increased heart rate, hypotension, or even MI, and 
is most commonly confirmed using 12-lead electrocardiogram (ECG) or 
continuous telemetry. 
POAF is most often detected on the second to third postoperative days 
and is frequently self-limiting and short-lived. Up to 80% of patients convert to 
sinus rhythm (SR) within 24 h, and six weeks after initial diagnosis 98% of 
patients have converted to SR (Aranki et al., 1996). Note that since the rate 
of POAF increases with age, POAF can be expected to be an increasing 
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problem in the large and growing population of elderly patients undergoing 
cardiac surgery (Amar et al., 2002). 
While POAF after cardiac surgery can be transient and without any 
consequences, it may lead to serious complications such as hemodynamic 
instability, cardiac failure, AKI, and stroke―and also to substantial economic 
costs (Ahlsson et al., 2009; Almassi et al., 1997; Steinberg, 2004). 
Furthermore, recent studies have indicated that POAF may play an even 
greater role in long-term mortality than previously believed, warranting more 
aggressive preventive and therapeutic measures (Phan et al., 2015). In a 
recent prospective, propensity score-matched (PSM) study, the effect of 
POAF following cardiac surgery on long-term survival was studied and was 
found to be in line with these observations. After close matching, based on 
patient comorbidity, extended POAF (lasting more than two days) was found 
to be associated with worse long-term survival (HR 1.97; 95% CI: 1.37‒2.80) 
(Sigurdsson et al., 2016).  
1.13.1 Risk factors for POAF 
As in the case of AKI, the pathophysiology of POAF is complex, incompletely 
understood, and multifactorial. Also, as in the case of AKI, inflammatory 
mechanisms―peaking on postoperative days 2 to 3―have also been 
implicated as predisposing to the development of POAF (Chung et al., 2001; 
Shlipak et al., 2003). What is more, a self reinforcing relationship between 
kidney dysfunction and POAF may be initiated by the pro-inflammatory effect 
of surgery (Fried et al., 2004). Pro-inflammatory cytokines have been shown 
to affect the expression and function of intracellular ion channels and 
electrical stability and conductance of current in the atrial myocyte 
membranes, predisposing to POAF (Friedrichs et al., 2011; Soliman et al., 
2010). Furthermore, the clearance of pro-inflammatory cytokines is reduced 
when there is significant renal dysfunction, further compounding the harmful 
effect of inflammation on heart function (Ak et al., 2005; Fried et al., 2004). 
Several perioperative factors have been reported as possible risk factors 
for POAF, both patient- and surgery-related (Peretto et al., 2014). Age has 
shown a consistent relationship with increased risk of POAF, which is 
believed to stem from both structural and electrophysiological changes in 
cardiovascular tissue with increasing age (Spach & Dolber, 1986; Zaman et 
al., 2000). Other reported risk factors include a previous history of cardiac 
disease (e.g. CAD, CHF, valvular heart disease, and cardiomyopathy), 
chronic obstructive pulmonary disease (COPD), obesity, increased 
perioperative ischemia, and postoperative infection (Ak et al., 2005; Aranki et 
al., 1996; Steinberg, 2004; Zacharias et al., 2005). Other risk factors that 
have been found to independently increase the risk of POAF in patients with 
AKI are age, low preoperative eGFR and hemoglobin, and nadir hematocrit 
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during CPB (Ng et al., 2016). Interestingly, these factors have also been 
associated with an increased risk of postoperative AKI (Hsu et al., 2008; 
Karkouti, 2012; Murphy et al., 2015). 
1.13.2  Treatment of POAF 
Management of POAF includes general measures, such as correction of 
underlying factors predisposing to arrhythmia, e.g. electrolyte and fluid 
deficits, specific pharmacological treatments (e.g. β-blockers and 
amiodarone), and non-pharmacological treatment (e.g. atrial pacing). 
However, all these treatments have variable efficacy and may adversely 
affect hemodynamic stability (Nair, 2010; Singhal & Kejriwal, 2010; Van 
Gelder et al., 2002; Wyse, 2011; Zimmer et al., 2003). Thus, identification of 
patients with several risk factors and at high risk of POAF after cardiac 
surgery is crucial for selection of those who might benefit from prophylactic 
therapy. β-blocker administration, the most used pharmacological 
prophylaxis, has been shown to significantly reduce the rate of POAF 
(Arsenault et al., 2013; Crystal et al., 2004). The European Society for 
Cardiothoracic Surgery therefore recommends it as the first choice in all 
patients who undergo open-heart surgery (Dunning et al., 2006). Amiodarone 
has also been shown to reduce the incidence of POAF, and to have an 
efficacy similar to that of β-blockers (Mitchell et al., 2005). 
1.13.3 Cardiovascular disease in Iceland 
One-third of all deaths in Iceland are attributable to CVD (Aspelund et al., 
2010). Despite a 70% decrease in the incidence of MI in Iceland from 1981 to 
2006, it remains the leading single cause of death, which is in line with other 
high-income nations (Aspelund et al., 2010). Moreover, the incidence of 
severe AS in Iceland is expected to increase greatly in coming decades, as 
evidenced in a recent study from Iceland where a random cohort of patients 
was evaluated with both computed tomography of the heart and 
echocardiography (Danielsen et al., 2014). As in other western countries, the 
largest increase is predicted to be in the population of patients who are 70 
years old or more. Many of these patients can be expected to require 
treatment, both medical and surgical, thereby placing great strain on 
healthcare systems (Danielsen et al., 2014). 
The first open-heart surgery using CPB, a form of CABG surgery, was 
conducted in Iceland on June 14, 1986 (Arnorsson, 2013) (Figure 9). Before 
that, Icelandic patients in need of open-heart surgery that required CPB had 
to be sent overseas for treatment. The number of surgeries has steadily 
increased since then and, to date, approximately 7,000 open-heart surgeries 
have been performed in Iceland (Guðbjartsson, 2016). Landspitali University 
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Hospital is the only center in Iceland where open cardiac surgery is 
performed, and currently four senior surgeons perform around 200‒250 
operations annually. In Iceland CABG still accounts for approximately two-
thirds of the operations, and this ratio has been fairly stable in the last ten 
years (Sigurjonsson et al., 2012). 
Figure 9. The first open-heart operation performed in Iceland with the aid of 
cardiopulmonary bypass technique. Photograph courtesy of Rannveig Þorvarðardóttir. 
The first AVR in Iceland was performed in September 1987 (Arnorsson, 
2013). By far the most common indication for AVR in Iceland is AS, followed 
by aortic valve regurgitation and endocarditis-related aortic valve disease 
(Ingvarsdottir et al., 2011) (Figure 10).  
Figure 10. Aortic stenosis in a bicuspid aortic valve (left) and a tricuspid aortic valve 
(right). Modified from http://www.mo-media.com/pathology/bicvpic.jpg and 
http://www.visualphotos.com/image/1x6067829/heart_valve_disease_aortic_stenosis. 
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Other open-heart procedures performed at the university hospital include 
mitral valve repair and replacement, aortic and tricuspid valve repair, thoracic 
aorta aneurysm repair, anti-arrhythmia procedures (MAZE), and surgery for 
congenital heart disease. For over a decade the outcome of most of the 
open-heart procedures conducted in Iceland has been extensively studied. 
Briefly, the results indicate a long-term outcome comparable to that in 
neighboring nations (Ingvarsdottir et al., 2011; Melvinsdottir et al., 2016; 
Oddsson et al., 2012; Ragnarsson et al., 2012; Sigurdsson et al., 2012; 
Sigurjonsson et al., 2012; Smarason et al., 2009; Steingrimsson et al., 2008; 
Viktorsson et al., 2011). The mortality rate is in the lower range, as is the rate 
of deep sternal wound infections (Steingrimsson et al., 2012). However, 
postoperative bleeding and the need for reoperation for bleeding is relatively 
high (Smarason et al., 2009) and patients remain at risk of other serious 
complications such as heart failure, AKI, and arrhythmias. 
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2 Aims 
2.1 Study I 
In this study, the goal was to determine the incidence of AKI in the ICU after 
meticulous identification of baseline SCr to overcome potential shortcomings 
of the RIFLE criteria. 
2.2 Study II 
We aimed to determine the incidence and the risk factors for AKI after 
myocardial revascularization surgery in a whole nation. Special emphasis 
was placed on the part that AKI, and subsequent recovery of renal function, 
plays in the postoperative prognosis―chiefly long-term kidney function and 
survival. 
2.3 Study III 
In this study, we evaluated the incidence and risk factors for AKI following 
aortic valve replacement on the indication of aortic stenosis. We also sought 
to study the short-term and long-term outcome in patients, including survival. 
2.4 Study IV 
This retrospective, population-based study was designed to evaluate different 
criteria for renal recovery, regarding the effect of recovery on long-term 
survival. We sought to examine factors affecting renal recovery following AKI 
after CABG and/or AVR, and also the relationship between AKI, recovery of 
renal function, and long-term survival.  
2.5 Study V 
The main aim was to evaluate risk factors for postoperative atrial fibrillation 
following myocardial revascularization surgery and AVR, in a whole nation, 
and to develop a model that might help in the preoperative identification of 
patients at highest risk of postoperative atrial fibrillation. In addition, we 
studied short-term postoperative complications, 30-day mortality, and long-
term survival. 
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3 Materials and methods 
An overview of the materials and methods of studies I‒V is given in Table VI. 
All the studies were single-center, nationwide, and retrospective in design, 
and they were performed on patients treated and operated at Landspitali 
University Hospital in Reykjavik. All the necessary study approvals were 
obtained from the Icelandic National Bioethics Committee and the Icelandic 
Data Protection Authority. 
3.1 Registers 
Several registers were used to identify and follow up patients, in an effort to 
minimize the amount of missing data. 
3.1.1  Centralized registers 
At Landspitali University Hospital, all patients who undergo surgery are 
registered in the institution‘s centralized electrical medical record system, 
called SAGA. Furthermore, patients who undergo open-heart surgery in 
Iceland are registered in a customized cardiac surgery database at the 
university hospital, the only institution performing cardiac surgery in Iceland. 
Relevant clinical information is continually registered in this database with the 
aim of quality control and further development of care of patients who 
undergo heart surgery. Individual patient information was obtained from 
patient charts, centralized laboratory databases, and surgical and 
anesthesiology reports. To ensure identification of all patients, the database 
was checked regularly against the hospital‘s electronic record system to 
confirm a 100% match. Lastly, in study IV, data on all patients ≥ 18 years of 
age who were admitted to ICUs in Iceland were collected from individual 
patient charts and registered. 
3.1.2  The National Patient Register 
The National Patient Register has been in use in Iceland since 2010. It has 
information on every patient‘s unique identification number, sex, age, place of 
residence, dates of admission to hospitals around the country, diagnoses 
according to the International Classification of Diseases, tenth revision (ICD-
10) codes, procedures, and electronic prescriptions for drugs. 
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Table VI: Overview of materials and methods.  
 Study I Study II Study III Study IV Study V 
Population ICU patients 
≥ 18 years old 
CABG patients AVR patients 
operated for AS ± 
CABG 
CABG ± AVR 
patients  
≥ 18 years old  
CABG ± AVR 
patients operated for 
AS  
Nr. of 
patients 
1,012 
 
1,710 
 
365 
 
1,834 744 
Period 2007 2001‒2013 2001‒2011 2007‒2015 2002‒2006 
Statistical 
analysis 
Multivariate 
logistic 
regression, 
Kaplan-Meier 
survival analysis, 
and Cox hazard 
regression 
analysis 
Logistic and Poisson 
regression, Kaplan-
Meier survival 
analysis, and 
multivariate Cox 
hazard regression 
analysis  
Logistic 
regression, 
Kaplan-Meier 
survival analysis, 
and multivariate 
Cox hazard 
regression 
analysis  
Receiver operator 
analysis, logistic and 
Cox hazard 
regression analysis, 
propensity score 
matching, and 
Kaplan-Meier 
survival analysis  
Logistic regression, 
Kaplan-Meier 
survival analysis, 
receiver operator 
analysis, and 
multivariate Cox 
hazard regression 
analysis 
Outcome 
measures 
Incidence of AKI, 
risk factors, 
survival, and rate 
of ESRD  
Incidence of AKI, 
renal recovery, and 
long-term survival  
Incidence of AKI, 
and short-term 
and long-term 
complications, 
including survival  
Definition of renal 
recovery, risk factors 
for non-recovery, and 
long-term survival  
Incidence of POAF, 
short-term 
complications, and 
short-term and long-
term survival 
AKI, acute kidney injury; AS, aortic stenosis; AVR, aortic valve replacement; CABS, coronary artery bypass surgery; ESRD, end-stage renal 
disease; ICU, intensive care unit. 
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3.1.1 The Icelandic End-Stage Renal Disease Registry 
The university hospital is the only center providing long-term RRT in Iceland 
and it records extensive information on all patients who undergo dialysis, 
such as indication, dialysis modality, and follow-up of kidney function. 
3.1.2  Statistics Iceland and the Icelandic Cause of Death Register 
All Icelandic citizens have a unique personal identification number consisting 
of ten digits, the date of birth and four control numbers. These unique 
numbers enable linkage of separate registries. All foreign-national patients 
who are admitted to Icelandic hospitals are allocated a personal identification 
number. All deaths must be reported to the Icelandic national population 
register, Statistics Iceland (www.statice.is). The Directorate of Health 
(Landlæknir, www.landlaeknir.is) handles registration of causes of death in 
the Icelandic Cause of Death Register. 
3.2 Study population 
3.2.1  Study I 
Patients were identified through a centralized database that records all ICU 
admissions at the university hospital. A total of 1,390 patients were admitted 
in 2007, from January 1 through December 31, 2007. Individuals under the 
age of 18 and those 364 patients who were re-admitted to the ICU were 
excluded. Fourteen other patients were excluded because of missing data, 
leaving 1,012 patients for final analysis. 
3.2.2  Study II 
All patients who underwent isolated CABG (on- or off-pump) from January 1, 
2001 through December 31, 2013 were identified through the centralized 
surgical registries already mentioned. Patients who concomitantly underwent 
other types of cardiac surgery (e.g. mitral valve repair or MAZE anti-
arrhythmia surgery) were excluded. In total 44 patients were excluded, 42 as 
they had missing baseline SCr values and two because they had end-stage 
kidney disease and were dependent on hemodialysis before the study. This 
left 1,710 patients for final analysis. The flow chart of the study population is 
shown in Figure 11. 
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Figure 11. Flow chart of the study population in study II. AKI, acute kidney injury; 
CABG, coronary artery bypass grafting; ESRD, end-stage renal disease; OPCAB, off-
pump coronary artery bypass; RRT, renal replacement therapy; SCr, serum creatinine 
(μmol/L). 
3.2.3  Study III 
All patients who underwent AVR due to AS ± CABG from January 1, 2001 
through December 31, 2011 were identified through the centralized surgical 
and diagnosis registries. Of the 436 patients who were operated during the 
10-year period, 71 patients were excluded: 31 due to a previous history of 
cardiac surgery, 27 because the indication for surgery was aortic 
regurgitation, and 13 due to missing data. 
3.2.4  Study IV 
All patients who underwent abdominal, cardiothoracic, vascular, or orthopedic 
surgery from January 1, 2007 through December 31, 2015 were identified 
through the centralized medical record system and were included. Altogether, 
27,685 individuals had 41,361 operations in total. Operations were grouped 
together according to surgical codes, based on the Nordic Medico-Statistical 
Committee Classification of Surgical Procedures (NCSP-IS, version 1.14, 
www.nowbase.org). Of the surgical cases identified, 1,917 (45.7%) were 
Stage 3 
N = 36 (2%) 
No AKI 
N = 1,526 
(89%) 
AKI 
N = 184 
(11%) 
Study sample 
Available baseline and 
postoperative SCr 
N = 1,710 (98%) 
Population 
CABG/OPCAB in 
Iceland 2001‒2013 
N = 1,754 
Excluded 
Missing baseline SCr 
N = 42 (2%) 
RRT for ESRD 
N = 2 (0%) 
 
Stage 1 
N = 121 (7%) 
Stage 2 
N = 27 (2%) 
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CABG and/or AVR. Of these patients, 83 were excluded as they had missing 
postoperative SCr values. The 327 patients identified with first-time AKI were 
analyzed further regarding recovery of renal function (Figure 12). Information 
on perioperative factors and registered ICD-10 diagnostic codes were 
collected from the centralized medical registry.  
 
Figure 12: Population flow chart in study IV. AKI, acute kidney injury; AVR, aortic 
valve replacement; CABG, coronary artery bypass grafting; OPCAB, off-pump 
coronary artery bypass; SCr, serum creatinine (μmol/L). 
3.2.5  Study V 
Patients who underwent CABG ± AVR on the indication of AS in Iceland from 
January 1, 2002 through December 31, 2006 were identified through a 
computerized diagnosis and operation registry together with the centralized 
open-heart surgery database. Altogether, 876 patients were identified and 
744 of them were included for further analysis. A flow chart of the study 
population is shown in Figure 13. 
Stage 3 
N = 28 (1.5%) 
No AKI 
N = 1,478 
(80.6%) 
AKI 
N = 356 
(19.4%) 
Study sample 
Baseline and postoperative 
SCr available 
N = 1,834 (95.7%) 
Excluded 
Missing baseline and/or 
postoperative SCr 
N = 83 (4.3%) 
 
Stage 1 
N = 253 (14.0%) 
Stage 2 
N = 46 (2.5%) 
Population 
CABG/OPCAB ± AVR  in 
Iceland 2007‒2015 
N = 1,917 
 
Excluded 
Repeat AKI episode 
N = 29 (1.6%) 
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Figure 13. Flow chart of the study population in study V. AF, atrial fibrillation; AVR, 
aortic valve replacement; CABG, coronary artery bypass graft; SR, normal sinus 
rhythm; POAF, postoperative atrial fibrillation. 
3.3 Data collection 
Information on clinical characteristics was collected from centralized registers 
and multiple variables were registered for each patient, including known risk 
factors for CVD, comorbidities, and previous medical history. Information on 
previous RRT was collected from the Icelandic End-Stage Renal Disease 
Registry. Data on perioperative or postoperative complications was collected 
from patient charts and also from anesthesiology and surgery reports. 
3.4 Risk scores and preoperative comorbidity classification 
In study I, the APACHE II score was calculated (Knaus et al., 1985). In 
studies II, III, and V, patients‘ preoperative symptoms were evaluated with the 
New York Heart Association (NYHA) classification (New York Heart 
Association. Criteria Committee. & New York Heart Association., 1979), and 
their standard EuroSCORE calculated (Roques et al., 1999). In study IV, the 
American Society of Anesthesiologists physical status classification (ASA 
score) was documented (Saklad, 1941). 
3.5 Laboratory methods 
Estimated GFR was derived from SCr using the CKD-EPI (Levey et al., 2009) 
and MDRD (Levey et al., 1999) equations in studies II and IV and studies I, 
III, and V, respectively.  
Population 
CABG +/- AVR in 
Iceland 2002‒2006 
N = 876 
Study sample 
N = 744 
SR 
N = 418 (66%) 
Excluded 
N = 132 
Missing data 
N = 23 
History of AF 
N = 109 
POAF 
N = 326 (44%) 
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CKD-EPI equation:  
eGFR = 141 × min(SCr/κ,1)
α
 × max(SCr/κ,1)
-1.209 
× 0.993
age
 [× 1.1018 if 
female] [× 1.159 if black] 
If female: κ = 0.7, α = −0.329 
If male: κ = 0.9, α = −0.411 
MDRD equation:  
eGFR = 186.3 × (SCr (in μmol/L)/88.4)
-1.154
 × age
-0.203
 (× 0.742 for females) 
3.6 Classification of AKI 
In studies II and IV, the KDIGO criteria (Khwaja, 2012) were used for 
classification of AKI and in studies I, III, and V we used the RIFLE criteria 
(Bellomo et al., 2004; Khwaja, 2012). As urine output was not always 
available, classification was based solely on SCr values and eGFR. Baseline 
SCr was classified as preoperative SCr closest to surgery, obtained within 30 
days of surgery.  
3.7 Classification of POAF 
POAF was diagnosed with a rhythm monitor/telemetry and/or ECG, with a 
duration of ≥ 5 min and/or initiation of treatment for AFib. At Landspitali, ECG 
monitoring is normally continuous for the first postoperative week after open-
heart surgery. 
3.8 Classification of complications and mortality 
Postoperative complications were categorized as either minor or major in 
studies II, III, and V. In studies II and III, minor complications included leg 
wound infection, POAF, urinary tract infection (UTI), pleural effusion requiring 
drainage, and pneumonia. Major complications included stroke, deep sternal 
wound infection (DSWI) with mediastinitis, endocarditis, MI (defined as 
isolated ST-segment changes or a new left bundle branch block on 
electrocardiogram along with elevation of creatine kinase MB of ≥ 70 μg/L), 
reoperation due to bleeding, sternum dehiscence and acute respiratory 
distress syndrome (ARDS)/multiple organ failure (MOF). In study V, minor 
complications included leg wound infection, UTI, and pneumonia; major 
complications included stroke, postcardiotomy mediastinitis, endocarditis, MI, 
AKI necessitating RRT, reoperation, sternum dehiscence, and ARDS/MOF. 
Operative mortality was classified as being death ≤ 30 days from surgery. 
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3.9 Outcome measures 
All-cause mortality (overall survival) was an outcome parameter in all the 
studies. Information on survival and cause of death was obtained from 
Statistics Iceland and the Icelandic Cause of Death Register, respectively. 
Other outcome measures for each study are described below. 
3.9.1 Study I 
The outcome measures were incidence of AKI, long-term survival, and rates 
of progression to ESRD. 
3.9.2  Study II 
This study focused on the incidence of AKI, short-term complications 
including  mortality, long-term survival, progression to ESRD, and ratio of 
RenR.  
3.9.3  Study III 
The outcome measures were incidence of AKI, short-term complications 
including mortality and risk of requiring dialysis therapy, long-term mortality, 
and rates of progression to ESRD. 
3.9.4  Study IV 
This study examined the ratio of renal recovery according to the optimal 
definition with regards to one-year survival. Risk factors for reduced long-
term survival were evaluated and five-year survival was compared between 
patients who recovered renal function and a propenisty score-matched group 
who did not. 
3.9.5  Study V  
The effect of POAF on short-term complications and mortality was examined, 
and long-term survival evaluated. 
3.10 Statistical analysis 
In studies I, II, and V, data collection was done using a standardized Excel 
data sheet (Microsoft Corp., Redmond, WA, USA). In study IV, all data were 
processed using custom JAVA scripts. In studies I‒III and V, all the statistical 
analyses were done using R statistical analysis software (R Foundation for 
Statistical Computing, Vienna, Austria). Study I was conducted using version 
2.12.0, study II using version 3.1.1, study III version 3.1.2, and study V 
version 2.12.1. The survival, Hmisc, MASS, stargazer, Greg, epicalc, 
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epitools, Resource Selection, FactoMine, MatchIt, and pROC packages were 
used. Statistical analysis in study IV was conducted in RStudio, version 0.98 
(R Development Core Team, 2015).  
Results are presented as mean/median ± standard deviation (SD), 
number of patients, and percent. The level of statistical significance was set 
at p < 0.05. Descriptive analysis was performed using the binary grouping of 
AKI (RIFLE classification Risk, Injury, or Failure or KDIGO classification of 
stage 1, stage 2, or stage 3 AKI) as opposed to no AKI in studies I‒IV, 
recovery versus non-recovery of renal function in study IV and NSR versus 
POAF in study V. Continuous variables were compared with the 2-sample 
Student’s t-test or Mann-Whitney rank-sum test (also known as the Wilcoxon-
Mann-Whitney test or the Wilcoxon rank-sum test) based on normality of the 
residuals for the data. In the Mann-Whitney test, statistics depend only on the 
ranks of the observations in the combined sample, as opposed to their raw 
values, and no assumption is made regarding population distribution 
(Ludbrook, 2008). The parametric Student´s t-test assumes a normal 
distribution and is more powerful than the non-parametric Mann-Whitney test 
(Ludbrook, 2008). Categorical variables were compared using either Fisher’s 
exact test or the chi-square test (Ludbrook, 2008). Fisher’s exact test is a 
way of testing association between two variables when the sample size is 
small, but the chi-square test is used when sample sizes are large. The chi-
square test works by computing the expected value for each cell if the 
relative risk were 1. The difference in observed and expected values is then 
combined into a chi-square approximation statistic and a p- value is 
computed. The Fisher exact test gives an exact answer no matter what the 
sample size is, but it is problematic as it assumes a fixed number of rows and 
columns in the experiment, which is not the case in the majority of 
experiments (Ludbrook, 2008). 
3.10.1 Calculation of incidence 
In studies I‒III, incidence included all cases of AKI diagnosed in the cohort. 
Paper III reported combined postoperative AKI incidence as well as incidence 
in isolated AVR and combined AVR +  lCABG. In study I, the incidence of AKI 
was calculated using both calculated and measured SCr baseline values. 
Paper IV reported the incidence of renal recovery as the proportion of 
patients who were alive on postoperative days 10, 20, and 30. In study V, 
incidence was calculated in the whole cohort as well as separately for 
patients undergoing CABG or CABG + AVR. In study II, change in incidence 
over time was assessed with a Poisson model.  
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3.10.2 Univariate and multivariate analysis of risk factors 
Univariate and multivariate logistic regression analysis was used to identify 
risk factors for AKI (studies I‒IV) and POAF (study V), as well as significant 
risk factors for postoperative complications, perioperative mortality, and 
progression to ESRD in study II. In study IV, univariate analysis was used to 
assess different criteria for renal recovery. Variables judged to be of clinical 
importance and variables with p-values of < 0.1 in descriptive analysis were 
used in stepwise multivariate logistic models. In study I, multivariate linear 
regression was used to correct for age in analysis of ICU stay. Cox 
proportional hazards models were used to assess the contribution of 
variables to long-term survival. Odds ratios (ORs) were used in logistic 
models and hazard ratios (HRs) in Cox models, with 95% confidence 
intervals (CIs). 
3.10.2.1 Study II 
The final model for evaluating preoperative risk factors of AKI was corrected 
for age, sex, body mass index (BMI), history of hypertension (HTN), DM (both 
insulin- and non-insulin-dependent) and CHF, preoperative eGFR, 
emergency surgery, and standard EuroSCORE. The model for evaluation of 
intraoperative and postoperative variables was corrected for operation time, 
use of inotropes, red blood cell (RBC) transfusions (per unit) intraoperatively 
and in the first postoperative week, reoperation, and postoperative 
complications that were significant in univariate analysis. Lastly, the model for 
predictors of long-term survival was corrected for KDIGO stage of AKI, age, 
sex, EuroSCORE, and major complications. 
3.10.2.2 Study III 
Risk factors for AKI were evaluated with a model corrected for transfused 
RBC units, CPB time, obesity (defined as BMI >30 kg/m
2
), insertion of intra-
aortic balloon pump (IABP), anemia (defined as hemoglobin (Hb) < 120 g/L in 
females and < 135 g/L in males), HTN, sex, preoperative CKD (defined as 
eGFR < 60 mL/min/1.73 m
2
) and age. The model for predictors of operative 
mortality was corrected for AKI, logistic EuroSCORE, RBC transfusion (in 
units), and CPB time (in min). Finally, the model for predictors of long-term 
survival was corrected for AKI, logistic EuroSCORE, RBC transfusion (per 5 
units), age, CPB time, sex, and obesity. 
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3.10.2.3 Study IV 
Univariate and multivariate logistic regression analysis was done to assess 
risk factors for decreased one-year survival of AKI patients. The multivariate 
regression analysis model was constructed using forward elimination to 
identify factors independently associated with one-year mortality. The final 
model was corrected for preoperative kidney dysfunction (defined as eGFR < 
60 mL/min/1.73 m
2
), neoplasm, CHF, ASA score 4/5, ischemic coronary 
disease, and renal recovery. A Cox proportional hazard model was used to 
analyze the association of renal recovery with long-term survival. The final 
model for preoperative factors was corrected for age, preoperative kidney 
dysfunction (defined as eGFR < 60 mL/min/1.73 m
2
), and CHF. The model 
for intraoperative and postoperative factors was corrected for reoperation, 
AKI stage, and renal recovery. Proportionality was assessed visually and with 
the logit function in R. 
3.10.3 Receiver operating characteristic curve 
In studies IV and V, the predictive ability of models was assessed by 
calculating the area under the receiver operating characteristic (ROC) curve. 
A ROC curve (sometimes called a sensitivity vs. (1 − specificity) plot) is 
created by plotting the true positive rate of a binary classifier system against 
the false positive rate at varying discrimination thresholds (Hanley & Mcneil, 
1982). This analysis can be used to select optimal models and discard 
suboptimal ones. 
3.10.4 Follow-up 
Patient survival was followed-up using information from Statistics Iceland and 
cause of death was documented from the Icelandic Cause of Death Register 
when possible.  
3.10.4.1 Study I 
The last follow-up date of survival was October 24, 2011. Median follow-up 
for patients with AKI was 11 months (range 0‒58), but it was 21.4 months 
(range 0‒58) in patients with normal kidney function.  
3.10.4.2 Study II 
In study II the last follow-up date of survival, using Statistics Iceland, was 
June 30, 2014 (with a mean follow-up time of 6.3 ± 3.6 years), and last 
follow-up date of SCr values or whether patients were receiving RRT was 
June 15, 2015 (with a mean follow-up time of 5.2 ± 3.9 years). Thirteen 
patients were lost to long-term follow-up of survival.  
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3.10.4.3 Study III 
The last follow-up date for death and cause of death was June 1, 2013 in 
study II, giving a mean follow-up time of 4.7 years (range 0‒11.2). No 
patients were lost to long-term follow-up. Patients were identified as 
deceased or living on September 1, 2010 and the cause of death was 
registered when available.  
3.10.4.4 Study IV 
In study IV the last follow-up date of survival was May 20, 2016. The median 
follow-up time in AKI patients was 38.9 months (interquartile range: 16.5‒
78.7). 
3.10.4.5 Study V 
The mean length of follow-up in study V was 5 years (range 0–8.1), and none 
of the patients were lost to follow-up.  
3.10.5 Survival analysis 
Survival analysis provides methods of comparing the risk of an event (most 
often death) between groups in a time-dependent fashion. The most 
commonly used methods were used in all the studies in the thesis, namely 
Kaplan-Meier to estimate survival curves, the log-rank test to compare 
groups statistically, and Cox´s proportional hazard analysis to test the effect 
of other variables on the event in question. 
The Kaplan-Meier method is used to measure the probability of surviving 
beyond a specified length of time (the survival function) by considering time 
in small intervals (Kaplan & Meier, 1958). It is often used to measure the 
proportion of patients living for a certain period after treatment/exposure. It is 
depicted as a series of declining or rising horizontal steps, sometimes shown 
with small vertical lines indicating individual events (Bewick et al., 2004). 
Comparison of survival curves was done with a log-rank test. This is used 
to test whether there is a difference between survival times in different 
groups, but does not permit other variables to be taken into account (Bewick 
et al., 2004). Cox´s proportional hazard analysis was used to assess the 
contribution of variables to long-term survival (Bewick et al., 2004) in studies 
II, III, and V.  
3.10.6 Propensity score matching 
In study IV, nearest-neighbor propensity score matching (PSMing) was used 
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to evaluate the connection between RenR and long-term survival. Each 
patient in the group that recovered renal function was assigned a control from 
the group that did not recover. Matching is based on the closest match to a 
distance measurement for the pair (Austin, 2011). The groups were matched 
in a 1:1 ratio with regard to age, preoperative kidney dysfunction (defined as 
eGFR < 60 mL/min/1.73 m
2
), neoplasm, ASA score 4/5, emergency surgery, 
operative time, and stage of AKI. PSM is used to attempt to reduce the bias 
introduced by confounding variables in observational statistics―in effect 
attempting to mimic study randomization (Ho et al., 2007) However, a 
disadvantage of PSM is that only observed covariates are accounted for, so a 
hidden bias may remain after matching (Garrido et al., 2014). Survival of the 
group that recovered renal function was thereafter compared to that of the 
PSM control group, using the Klein and Moeschberger test (Klein & 
Moeschberger, 2003). 
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4 Results 
4.1 Study I – Identification of baseline kidney function 
4.1.1  Patient characteristics 
Altogether, 220 ICU patients (22%; 95% CI: 19‒24) were found to have AKI 
according to the RIFLE criteria. Of these patients 7% (95% CI: 6‒9) were in 
the Risk class, 7% (95% CI: 5‒9) were in the Injury class, and 8% (95% CI: 
6‒10) were in the Failure class. The distribution of AKI in each subgroup of 
the RIFLE classification can be seen in Figure 14, which also shows that the 
proportion of patients who experienced AKI increased with age (p < 0.001). 
However, the distribution between subgroups of the classification did not 
change significantly with age. The proportion of males was 61% in the whole 
study, and no significant difference was seen in sex distribution between the 
patients who had AKI and those who did not. The average APACHE II score 
of AKI patients was 23 ± 8 (median 22; range: 7‒48). 
Figure 14. The absolute proportion of patients admitted to the intensive care unit 
(ICU) who met the RIFLE criteria for acute kidney injury (AKI), and their distribution in 
the Risk, Injury, and Failure subgroups. The distribution for all patients (All) is shown, 
and also the distribution for different age groups. The numbers above each column 
show the number of patients in each subgroup. The percentage value indicates the 
relative proportion of each RIFLE group in each age group. 
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4.1.2 Estimated versus measured baseline SCr 
Baseline SCr was widely available in the study population (in 218 of 220 
patients in the AKI group and 592 of 792 patients in the non-AKI group). 
Table VII shows a comparison of the RIFLE classification using the measured 
and estimated baseline SCr values. Using the estimated SCr values led to an 
overestimation of the rate of AKI (4% absolute and 16% relative 
overestimation; p<0.001) and resulted in the correct RIFLE subgrouping for 
82% of the patients. Compared to using measured SCr, estimated values had 
a sensitivity of 76% (95% CI: 73‒79), a specificity of 95% (95% CI: 94‒97), a 
positive predictive value of 88% (95% CI: 83‒91), and a negative predictive 
value of 90% (95% CI: 89‒91). 
Table VII: Classification of intensive care unit patients into the RIFLE subgroups of 
AKI using either measured or estimated baseline creatinine derived from eGFR 75 
according to the MDRD equation. 
  Measured SCr 
  Non-AKI Risk Injury Failure 
Estimated SCr Non-AKI 533 21 5 1 
 Risk 40 28 12 0 
 Injury 18 19 31 6 
 Failure 1 4 21 70 
AKI, acute kidney injury; Cr, creatinine; MDRD, Modification of Diet in Renal Disease; 
SCr, serum creatinine. 
4.1.3  Risk factors for AKI 
Table VIII shows the frequency of previously defined risk factors for AKI and 
also the contributory causes to the development of AKI in patients in each 
RIFLE subgroup. The most common risk factor was ischemic heart disease, 
cardiogenic shock was the most common contributory cause and, of all types 
of surgery, AKI was most common after cardiac procedures. 
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Table VIII: The frequency of comorbid diseases and contributory causes of AKI 
according to the RIFLE classification. Numbers of patients and percentages within 
parenthesis are given, except for absolute numbers, where median and range are 
given. 
 Risk Injury Failure 
n (%) 72 (100) 69 (100) 79 (100) 
Risk factors for AKI  2 (0-4) 1 (0-5) 1 (0-4) 
   Decreased eGFR 20 (28) 10 (14) 23 (29) 
   IHD 37 (51) 29 (42) 33 (42) 
   HTN 33 (46) 25 (36) 32 (41) 
   DM1 1 (1) 2 (3) 2 (3) 
   DM2 7 (10) 6 (9) 14 (18) 
   COPD 25 (35) 10 (14) 11 (14) 
   Liver disease 3 (4) 3 (4) 2 (3) 
Cause of AKI 1 (0-3) 1 (0-3) 1 (0-4) 
   Postoperative 30 (42) 23 (33) 24 (30) 
   Cardiogenic shock 33 (46) 29 (42) 27 (34) 
   Septic shock 13 (18) 20 (29) 25 (32) 
   Hypovolemic shock 5 (7) 5 (8) 4 (6) 
   Respiratory failure 29 (40) 22 (32) 27 (34) 
   Trauma 6 (8) 4 (6) 2 (3) 
   Medication 2 (3) 7 (10) 8 (10) 
   Bleeding 3 (4) 3 (4) 5 (6) 
AKI, acute kidney injury; COPD, chronic obstructive pulmonary disease; DM, diabetes 
mellitus; eGFR, estimated glomerular filtration rate; HTN, hypertension; IHD, ischemic 
heart disease. 
4.1.4  Complications and survival 
Incidence of RRT and length of ICU stay was inversely associated with the 
severity of AKI. Only three of the 119 patients who developed AKI, and 
survived for more than three months, needed chronic RRT for ESKD. 
Median length of follow-up for patients with AKI was 11 months (range: 0‒
58) and it was 21 months (range: 0‒58) in non-AKI patients. ICU mortality 
increased in accordance with the severity of AKI (9%, 11%, 39%, and 39% 
for the non-AKI, Risk, Injury, and Failure subgroups, respectively; p < 0.001). 
If estimated SCr was used instead of measured SCr, the mortality was 11%, 
24%, and 38% for the Risk, Injury, and Failure subgroups, respectively. 
Similar trends were seen for hospital mortality. Following correction for 
comorbid causes, contributory factors to AKI, and age, the Injury and Failure 
subgroups proved to be significant risk factors for mortality (as compared to 
the Risk subgroup). 
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Figure 15 depicts the one-year survival of patients in study I. One-year 
survival was found to be 84%, 63%, 45%, and 45% for the non-AKI, Risk, 
Injury, and Failure subgroups, respectively, (p < 0.001) and was similar 
whether we used measured or estimated SCr. 
Figure 15. One-year survival of patients admitted to Icelandic intensive care units 
based on classification according to the RIFLE criteria. AKI, acute kidney injury. 
4.2 Study II – AKI following CABG 
4.2.1  Patient characteristics 
The incidence of AKI was found to be 11% in patients who underwent 
surgical myocardial revascularization. Figure 16 shows the annual 
percentage of patients who experienced AKI during the period. Poisson 
regression analysis revealed a significant overall decreasing trend in 
incidence during the study time (p = 0.01), with an incidence rate ratio of 0.95 
annually. 
Preoperatively, 236 patients had CKD, three at stage 5, 17 at stage 4, 62 
at stage 3B, and 154 at stage 3A. Of those 184 patients who experienced 
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postoperative AKI, 60 had CKD preoperatively. Of the 184 patients, 121 (7%) 
had stage 1 AKI, 27 (2%) had stage 2 AKI, and 36 (2%) had stage 3 AKI. 
Figure 16. Annual percentage of acute kidney injury (AKI) in patients in study II. 
Roughly 80% (n=1,398) of operated patients were male, but there was no 
significant difference in sex distribution between the groups with and without 
AKI. Patients with AKI were on average three years older, had significantly 
higher preoperative risk scores, and were more likely to have undergone 
emergency surgery. Except for diabetes there was, however, no significant 
difference between the groups regarding the conventional risk factors for 
CAD (sex, HTN, family history of CAD, smoking, and dyslipidemia). No 
significant difference was seen regarding extent of CAD, history of CHF, or 
COPD, but patients who experienced AKI were more likely to have suffered 
preoperative MI or acute CHF (Table IX). 
The AKI group had significantly higher preoperative SCr values (95 vs. 90 
mol/L, respectively) and they were more likely to have had preoperative 
CKD (eGFR ≤ 60 mL/min/1.73 m
2
). Preoperatively, mean SCr was 94 mol/L 
for men and 79 mol/L for women. 
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Table IX: Baseline characteristics of patients in study II, classified as either AKI 
(stage 1, 2, and 3 AKI of the KDIGO criteria
a
) or no AKI. 
 
Total 
n = 1,710 
No AKI 
n = 1,526 
AKI 
n = 184 
 
p-value 
Diabetes  270 (16) 225 (15) 45 (25) 0.001 
Statin use  1,283 (78) 1,139 (78) 144 (81) 0.39 
BMI 28 ± 4 28 ± 4 29 ± 5 0.057 
History of MI 383 (23) 331 (22) 52 (29) 0.048 
Preoperative CCS score    0.023 
  0  11 (1) 11 (1) 0 (0)  
  1  83 (5) 77 (5) 6 (3)  
  2  324 (19) 302 (20) 22 (12)  
  3  548 (32) 487 (32) 61 (33)  
  4  723 (43) 629 (42) 94 (51)  
Preoperative LVEF, % 55 ± 10 55 ± 10 55 ±  12 0.87 
Preoperative NYHA score    0.003 
  0  185 (13) 175 (14) 10 (7)  
  1  98 (7) 90 (7) 8 (5)  
  2  363 (26) 336 (27) 27 (18)  
  3  473 (34) 411 (33) 62 (42)  
  4  289 (21) 249 (20) 40 (27)  
History of arrhythmia 174 (10) 155 (10) 19 (10) 0.9 
Pre-existing CKD 236 (14) 176 (12) 60 (33) < 0.001 
Preoperative SCr 91 ± 31 90 ± 25 95 ± 39 0.42 
Preoperative eGFR  82 ± 19 83 ± 18 72 ± 23 < 0.001 
Preoperative eGFR     < 0.001 
     ≥ 90 
     60‒89 
     45‒59 (CKD stage 3A) 
     30‒44 (CKD stage 3B) 
     15‒29 (CKD stage 4) 
     < 15 (CKD stage 5) 
649 (38) 
825 (48) 
154 (9) 
62 (4) 
17 (1) 
3 (0) 
607 (40) 
743 (49) 
122 (8) 
43 (3) 
9 (1) 
2 (0) 
42 (23) 
82 (45) 
32 (17) 
19 (10) 
8 (4) 
1 (1) 
 
COPD 120 (7) 106 (7) 14 (8) 0.65 
Preoperative Hb 141 ± 14.3 142 ± 14 135 ± 16 < 0.001 
Emergency surgery 80 (5) 61 (4) 19 (10) < 0.001 
Preoperative MI 466 (27) 405 (27) 61 (33) 0.066 
CHF 231 (14) 193 (13) 38 (21) 0.004 
Standard EuroSCORE 5 (± 3) 5 (± 3) 6 (± 4) < 0.001 
a
KDIGO stages:  stage 1 = increase in SCr of ≥ 26.5 µmol/L within 48 h or 1.5‒1.99 
times baseline within seven days; stage 2 = increase in SCr to 2‒2.99 times baseline; 
stage 3 = increase in SCr to three times baseline or ≥ 354 µmol/L, or initiation of renal 
replacement therapy.  
Mean and standard deviations are shown for continuous variables and percentages 
are given within parenthesis. 
AKI, acute kidney injury; BMI, body mass index in kg/m
2
; CABG, coronary artery 
bypass grafting; CCS, Canadian Cardiovascular Society; eGFR, estimated glomerular 
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filtration rate in mL/min/1.73 m
2
; Hb, hemoglobin in g/L; HF, heart failure; IHD, 
ischemic heart disease; LVEF, left ventricular ejection fraction; MI, myocardial 
infarction; NYHA, New York Heart Association; PCI, percutaneous coronary 
intervention; SCr, serum creatinine in μmol/L. 
4.2.2  Operative factors and postoperative complications 
Patients with AKI who underwent CABG had on average CPB times that 
were 15 min longer, and total operative times (skin-to-skin) were 13 min 
longer in the AKI group. The AKI group was more likely to need intraoperative 
inotrope support, but there was no significant difference between the groups 
regarding the type of surgery performed, i.e. conventional CABG or OPCAB. 
Postoperatively, AKI patients had longer hospital and ICU stays, had more 
postoperative bleeding, and received three times as many units of packed 
RBCs than patients who did not sustain AKI. Furthermore, the AKI group was 
more likely to need postoperative RRT (either CRRT or intermittent 
hemodialysis) (Table X). The most common postoperative complication was 
POAF, which was significantly more likely to be diagnosed in the group that 
had AKI than in those who did not (53% vs. 38%; p = 0.001). Operative death 
was significantly higher in the AKI group (9% vs. 2%; p < 0.001), and AKI 
proved to be an independent predictor of both minor and major 
complications, with an OR of 1.78 (95% CI: 1.29‒2.47; p < 0.001) and 2.49 
(95% CI: 1.65‒3.76; p < 0.001), respectively. 
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Table X: Intraoperative and postoperative characteristics of patients in study II, 
classified as either AKI (stage 1, 2, and 3 AKI of the KDIGO criteria
a
) or no AKI. 
 
 
Total 
n = 1,710 
No AKI 
n = 1,526 
AKI 
n = 184 
 
p-value 
Surgical procedure: CABG vs. 
OPCAB 
1,350 (79) 1,202 (79) 148 (80) 0.63 
CPB time, min 91 ± 34 89 ± 31 104 ± 50 < 0.001 
X-clamp time, min 47 ± 17 47 ± 17 50 ± 23 0.25 
Total operative time, min 212 ± 57 211 ± 54 224 ± 74 0.041 
Use of IABP 92 (5) 76 (5) 16 (9) 0.054 
Intraoperative inotrope use 885 (53) 776 (52) 109 (60) 0.028 
Postoperative bleeding, mL 985 ± 1,018 942 ± 636 1,341 ± 2,478 0.002 
RBC transfusion, units
b
 3 ± 4 2 ± 3 6 ± 7 < 0.001 
ICU stay, days
 
2 ± 3 2 ± 3 3 ± 6 < 0.001 
Total hospital stay, days
 
11 ± 8 11 ± 7 14 ± 12 < 0.001 
Death < 30 days 40 (2) 24 (2) 16 (9) < 0.001 
RRT for AKI  19 (1) 0 (0) 19 (10) < 0.001 
Postoperative SCr 102 ± 55 98 ± 44 137 ± 105 < 0.001 
ESRD 5 (0.3) 4 (0.3) 1 (0.5) 0.43 
Major complication 183 (11) 144 (10) 39 (21) < 0.001 
   Stroke 9 (1) 8 (1) 1 (1) 1 
   Mediastinitis 17 (1) 15 (1) 2 (1) 0.7 
   Myocardial infarction 82 (5) 66 (4) 16 (9) 0.016 
   Reoperation due to bleeding 118 (7) 95 (6) 23 (13) 0.003 
   Sternum dehiscence 26 (2) 21 (1) 5 (3) 0.19 
   ARDS or MOF 53 (3) 35 (2) 18 (10) < 0.001 
Minor complication 834 (49) 723 (48) 111 (60) 0.001 
   POAF 671 (39) 574 (38) 97 (53) 0.001 
   Leg wound infection 179 (11) 159 (10) 20 (11) 0.8 
   Urinary tract infection 59 (4) 50 (3) 9 (5) 0.28 
   Pleural effusion 191 (11) 160 (11) 31 (17) 0.013 
   Pneumonia 113 (7) 94 (6) 19 (10) 0.04 
a
KDIGO stages:  stage 1 = increase in SCr of ≥ 26.5 µmol/L within 48 h or 1.5‒1.99 
times baseline within seven days; stage 2 = increase in SCr to 2‒2.99 times baseline; 
stage 3 = increase in SCr to three times baseline or ≥ 354 µmol/L, or initiation of RRT.  
b
Units of RBCs transfused intraoperatively and during the first postoperative week. 
Mean and standard deviations are given for continuous variables and percentages are 
shown in parenthesis. 
AKI, acute kidney injury; ARDS, acute respiratory distress syndrome; CABG, coronary 
artery bypass grafting; CPB, cardiopulmonary bypass; ESRD, end-stage renal 
disease; IABP, intra-aortic balloon pump; ICU, intensive care unit; MOF, multiple 
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organ failure; OPCAB, off-pump coronary artery bypass; POAF, postoperative atrial 
fibrillation; RBC, red blood cell; RRT, renal replacement therapy; SCr, serum 
creatinine in umol/L. 
4.2.3  Risk factors for AKI 
Independent risk factors for AKI were found to be preoperative eGFR, BMI, 
DM, standard EuroSCORE, units of packed RBCs transfused intraoperatively 
and in the first postoperative week, and reoperation due to bleeding (Table 
XI).  
Table XI: Independent risk factors for AKI in study II. 
 
Unadjusted OR (95% 
CI) 
Adjusted OR (95% 
CI) 
p-value 
BMI 1.04 (1.01‒1.08) 1.04 (1‒1.08) 0.037 
Diabetes 1.94 (1.34‒2.82) 1.66 (1.11‒2.47) 0.016 
Preoperative mean eGFR  0.97 (0.96‒0.98) 0.97 (0.96‒0.98) < 0.001 
EuroSCORE 1.08 (1.01‒1.15) 1.11 (1.06‒1.16) < 0.001 
RBC transfusion, units
a
 1.19 (1.13‒1.25) 1.23 (1.16‒1.31) < 0.001 
Reoperation due to bleeding
 2.07 (1.09‒3.94) 0.37 (0.15‒0.93) 0.024 
a
Units of RBCs transfused intraoperatively and during the first postoperative week. 
BMI, body mass index in kg/m
2
; eGFR, estimated glomerular filtration rate in 
mL/min/1.73 m
2
; OR, odds ratio; RBC, red blood cell. 
4.2.4  Renal recovery and long-term kidney function 
AKI was found to be a significant risk factor for development of CKD (HR 
2.08; 95% CI: 1.49‒2.9; p < 0.001) but not ESRD. On postoperative day 10, 
the majority of patients who experienced AKI had recovered renal function 
(defined as an SCr ratio of < 1.25 of baseline). On postoperative day 20, 
almost 95% of the patients had recovered their kidney function (Figure 17). 
Regression analysis showed that patients who had recovered renal function 
had a higher probability of long-term survival than those who did not (OR 
0.38; 95% CI: 0.2‒0.73; p = 0.004 vs. OR 0.16; 95% CI: 0.06‒0.39; p < 0.001, 
respectively). 
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Figure 17. Kaplan-Meier plot of recovery of renal function (defined as an SCr ratio of 
< 1.25 baseline SCr) in patients in study II. AKI, acute kidney injury. 
4.2.5  Survival 
                                                                                                                                                                                                                                        
Figure 18 shows the substantial difference in survival between patients with 
no AKI and patients with AKI. Survival was inversely associated with the 
severity of AKI, and the 10-year survival of patients without AKI and those 
with AKI of stages 1, 2, and 3 was 76%, 63%, 56%, and 49%, respectively (p 
< 0.001). Patients in the Failure group had a fourfold higher risk of dying than 
patients with no AKI (log-rank test, p < 0.001). 
                                                                                                                                                                                                                                        
Figure 18. Kaplan-Meier curve showing comparison of survival of patients with no AKI 
and those with AKI in study II. AKI, acute kidney injury. 
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Finally Table XII shows the independent risk factors for mortality. The 
interaction between POAF (the single most common postoperative 
complication) and AKI was not found to significantly affect long-term 
mortality. However, upon testing of possible interaction, only POAF was 
significantly correlated to long-term survival in a model that was also 
corrected for age, sex, preoperative standard EuroSCORE, and the diagnosis 
of at least one major complication (adjusted OR 1.63; 95% CI: 1.2‒2.2; p = 
0.002). 
Table XII: Independent risk factors for long-term mortality in study II. The model was 
corrected for extent of acute kidney injury (AKI), age, sex, standard EuroSCORE, and 
major complications. 
 HR (95% CI) p-value 
KDIGO AKI: 
   Stage 1   
   Stage 2 
   Stage 3 
 
1.42 (0.99‒2.04) 
1.65 (0.84‒3.22) 
2.02 (1.22‒3.33) 
 
0.059 
0.143 
< 0.001 
Age (per year) 1.02 (1.01‒1.04) < 0.001 
Standard EuroSCORE 1.22 (1.18‒1.26) < 0.001 
Major complications 1.86 (1.40‒2.48) < 0.001 
AKI, acute kidney injury. 
4.3 Study III – AKI following AVR 
4.3.1  Baseline patient characteristics 
Patient characteristics of the cohort in study III are shown in Table XIII. The 
majority of patients were male (n = 230) and the average age was 71 (± 10) 
years. The majority of surgeries (55%) were concomitant AVR and CABG 
surgery. Half of the patients (n = 184) received a stentless biological 
prosthesis, 31% a stented biological prosthesis (n = 114), and 18% (n = 67) a 
mechanical valve.  
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Table XIII: Baseline patient characteristics of patients in study III. Patients were 
classified as either having AKI (in the classes Risk, Injury, or Failure of the RIFLE 
criteria
a
) or not having AKI. Mean and standard deviations are shown for continuous 
variables and percentages are shown in parentheses. 
 
No AKI 
n = 283 
AKI 
n = 82 
p-value 
Male 188 (66) 42 (51) 0.017 
BMI 27 ± 4 29 ± 6 0.01 
DM 34 (12) 20 (24) 0.01 
HTN 189 (67) 65 (79) 0.043 
Dyslipidemia 117 (42) 38 (46) 0.51 
History of smoking 189 (67) 44 (54) 0.041 
History of MI 29 (10) 19 (23) 0.005 
History of chronic HF 49 (17) 29 (35) 0.001 
Reduced preoperative renal function
b
 72 (25) 37 (45) 0.001 
Preoperative SCr 93 ± 44 98 ± 27 0.25 
Preoperative Hb 139 ± 13 132 ± 15 < 0.001 
Preopartive anemia
c
 65 (24) 29 (35) 0.034 
NYHA score III‒IV 159 (56) 61 (74) 0.005 
EuroSCORE, log 8 ± 10 14 ± 15 0.001 
Preoperative left ventricular EF 57 ± 9 55 ± 9 0.15 
a
RIFLE: Risk = increase in SCr of ×1.5 or decrease in GFR of > 25%; Injury = 
increase in SCr of ×2 or decrease in GFR of > 50%; Failure = increase in SCr of ×3, a 
decrease in GFR of > 75%, or SCr ≥ 354 µmol/L concomitant with an acute rise in SCr 
of ≥ 44 µmol/L. 
b
Defined as eGFR < 60 mL/min/1.73 m
2
. 
c
Defined as Hb < 120 g/L in females and < 135 g/L in males. 
AKI, acute kidney injury; BMI, body mass index in kg/m
2
; DM, diabetes mellitus; EF, 
ejection fraction; Hb, hemoglobin in g/L; HF, heart failure; HTN, hypertension; MI, 
myocardial infarction; NYHA, New York Heart Association; SCr, serum creatinine in 
μmol/L. 
A total of 82 patients (23%) developed AKI according to the RIFLE 
criteria; 40 (11%) in the Risk class, 28 (8%) in the Injury class, and 14 (4%) in 
the Failure class. The group that experienced AKI was older on average (74 
years vs. 70 years; p < 0.001), had more comorbidity, had higher 
preoperative risk assessment scores, and were more likely to have reduced 
preoperative kidney function. 
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4.3.2  Intraoperative characteristics and postoperative 
complications 
Intraoperatively, patients who experienced AKI had longer aortic X-clamp and 
total operative time, and perioperatively they were more likely to need 
insertion of an IABP. There was no significant difference regarding whether 
patients underwent emergency surgery or whether they had concomitant 
CAGB surgery together with AVR. 
The postoperative complications are also given in Table XIV. 
Complications were generally more common in the AKI group―both minor 
and severe. As was the case following isolated CABG, the most common 
postoperative complication was POAF (diagnosed in 68% of patients (n = 
249)). There was, however, no significant difference in rates of POAF 
between the group that experienced AKI and the group that did not. Patients 
with AKI were also transfused significantly more units of packed red blood 
cells. Median length of stay in the surgical ward was four days longer (13 vs. 
9; p < 0.001) and ICU stay was five days longer (6 vs. 1; p < 0.001). Fifteen 
patients (4%) received RRT postoperatively, four of whom died while on 
CRRT, and six patients continued to have intermittent hemodialysis following 
discharge from the ICU. Only one patient (0.3%) developed ESRD and 
required RRT for more than three months postoperatively. 
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Table XIV: Intraoperative characteristics and postoperative complications of patients 
in study III. Patients were classified as either having AKI (in the classes Risk, Injury, 
or Failure of the RIFLE criteria
a
) or not having AKI. Means and standard deviations 
are shown for continuous variables and percentages are shown in parentheses. 
 
No AKI 
n = 283 
AKI 
n = 82 
p-value 
Emergency surgery 4 (1) 1 (1) 0.86 
Urgent surgery 23 (8) 17 (21) 0.003 
IABP 8 (3) 15 (18) < 0.001 
CABG 150 (53) 49 (60) 0.34 
Aortic clamp time, min 111 ± 31 135 ± 40 < 0.001 
CPB time, min 151 ± 46 191 ± 58 < 0.001 
Stented biological valve 86 (30) 28 (34) 0.61 
Stentless biological valve 138 (49) 46 (56) 0.3 
Mechanical valve 59 (21) 8 (10) 0.034 
Lowest intraoperative temperature (°C) 35 ± 1 35 ± 1 0.2 
Minor complications 171 (60) 69 (84) < 0.001 
    Superficial wound infection 19 (7) 11 (13) 0.086 
    POAF 185 (65) 64 (78) 0.086 
    Pleural effusion 25 (9) 24 (29) < 0.001 
    Pneumonia 16 (6) 24 (29) < 0.001 
    UTI 11 (4) 28 (34) < 0.001 
    TIA 5 (2) 2 (2) 0.66 
Major complications 63 (22) 53 (65) < 0.001 
    MI 25 (9) 24 (29) < 0.001 
    Sternal dehiscence 3 (1) 4 (5) 0.048 
    Stroke 6 (2) 2 (2) 1 
    Deep sternal infection 3 (1) 1 (1) 1 
    Reoperation due to bleeding 31 (11) 23 (28) < 0.001 
First 24 h bleeding, mL 1,060 ± 771 1,320 ± 1,064                                              0.041
RBC transfusion, units 6 ± 6 13 ± 11 < 0.001 
Length of stay in ICU, days 1 (0‒15) 6 (1‒80) < 0.001 
Length of stay in surgical ward, days 9 (0‒41) 13 (0‒127) < 0.001 
≤ 30-day operative mortality 6 (2) 15 (18) < 0.001 
a
RIFLE: Risk = increase in SCr of ×1.5 or decrease in GFR of > 25%; Injury = 
increase in SCr of ×2 or decrease in GFR of > 50%; Failure = increase in SCr of ×3, a 
decrease in GFR of > 75%, or SCr ≥ 354 µmol/L concomitant with an acute rise in SCr 
of ≥ 44 µmol/L. 
AKI, acute kidney injury; CABG, coronary artery bypass grafting; CPB, 
cardiopulmonary bypass; IABP, intra-aortic balloon pump; ICU, intensive care unit; MI, 
myocardial infarction; POAF, postoperative atrial fibrillation; RBC, red blood cell; SCr, 
serum creatinine in μmol/L; TIA, transient ischemic attack; UTI, urinary tract infection. 
4.3.3  Risk factors for AKI 
Multivariate analysis revealed that independent predictors of AKI were 
packed RBC transfusions (OR 1.64; 95% CI: 1.33‒2.07 per 5 units), longer 
CPB time (OR 1.10; 95% CI: 1.04‒1.15 per 10 min), and obesity (BMI > 30 
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kg/m
2
) (OR 2.71; 95% CI: 1.41‒5.22). 
4.3.4  Survival 
Operative mortality was ninefold higher in the AKI group (18% vs. 2%; p < 
0.001). After adjusting for standard EuroSCORE, CPB time, and transfusions 
of RBCs, AKI proved to be an independent predictor of 30-day mortality. 
Furthermore, AKI patients had significantly lower five-year survival than 
patients with normal postoperative kidney function (66 vs. 87%; p < 0.001). 
However, AKI was not predictive of long-term survival (HR 1.44; 95% CI: 
0.86‒2.42). 
4.4 Study IV – Recovery of renal function following AKI 
In total, 41,361 operations were performed on 27,685 individuals during 
the study period. The majority were orthopedic surgery (17,821 operations; 
43.1%), followed by abdominal surgery (13,129 operations; 31.7%), vascular 
surgery (5,285 operations; 12.8%), and cardiothoracic surgery (5,126 
operations; 12.4%) (Figure 19). In this chapter of the thesis, only outcome of 
CABG and/or AVR operations will be analyzed further, i.e. 1,917 of the 
41,361 operations (4.6%). Baseline and postoperative SCr was available in 
1,834 (95.7%) of these operations and could therefore be included in the 
study.  
 
Figure 19. Types and proportions of surgeries included in study IV. 
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A total of 356 patients who underwent open-heart surgery (19.4%) had 
complications involving postoperative AKI. Of these cases, 29 repeat AKI 
cases were excluded, leaving a total of 327 cases of AKI that was diagnosed 
for the first time for further analysis. Of these cases, 253 (14.0%), 46 (2.5%), 
and 28 (1.5%) were stage 1, stage 2, and stage 3, respectively, according to 
the KDIGO criteria. 
4.4.1 Assessment of criteria for renal recovery 
Analysis according to pre-specified criteria for renal recovery (see Materials 
and methods) showed recovery rates varying from 52% to 95% (Table XV). 
Table XV: Renal recovery of individuals with AKI at postoperative days 10, 20, and 30 
in study IV. 
Criteria 10 days 
(n = 297) 
20 days 
(n = 291) 
30 days 
(n = 290) 
SCr  < 1.5 × baseline 254 (85.6) 254 (87.3) 254 (87.6) 
SCr  < 1.25 × baseline 203 (68.4) 210 (72.2) 214 (73.8) 
SCr  < 1.10 × baseline  154 (51.9) 127 (56.4) 165 (56.9) 
a
Recovering eGFR > 60 142 /150 (94.7) 143/150 (95.3) 143/150 (95.3) 
Recovering preoperative 
CKD category
 
   
        3A (eGFR > 45) 78/90 (86.7) 79/88 (89.8) 80/87 (92.0) 
        3B (eGFR > 30) 41/49 (83.7) 41/46 (89.1) 42/46 (91.3) 
        4 (eGFR > 15) 15/20 (75.0) 15/20 (75.0) 15/20 (75.0) 
Data are number (percentage). 
a
Individuals with baseline eGFR ≤ 60 mL/min/1.73 m
2
 were excluded from analysis. 
eGFR, estimated glomerular filtration rate in mL/min/1.73 m
2
; SCr, serum creatinine. 
ROC analysis of the specified criteria (as listed in Materials and methods) 
revealed that all the criteria had poor ability to predict one-year mortality, with 
AUC in the 0.3‒0.6 range (Figure 20, Table XVI). 
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Figure 20. Graphic representation of ROC analysis of predictive value of renal 
recovery (to SCr < 1.5 × baseline SCr) on one-year mortality of patients in study IV.  
Table XVI: Comparison of different renal recovery criteria at 10, 20, and 30 days after 
surgery, and their relation to one-year survival of patients in study IV. 
 Cases Controls AUC 95% CI 
< 1.5 × baseline SCr     
10 days 284 13 0.63 0.49‒0.76 
20 days 284 7 0.51 0.37‒0.65 
30 days 284 6 0.52 0.36‒0.69 
< 1.25 × baseline SCr     
10 days 284 13 0.54 0.40‒0.68 
20 days 284 7 0.43 0.29‒0.57 
30 days 284 6 0.45 0.29‒0.62 
< 1.10 × baseline SCr     
10 days 284 13 0.49 0.35‒0.63 
20 days 284 7 0.35 0.21‒0.49 
30 days 284 6 0.37 0.20‒0.53 
eGFR > 60     
10 days 149 1 0.47 NA-NA 
20 days 149 1 0.48 NA-NA 
30 days 149 1 0.48 NA-NA 
AUC, area under curve; eGFR, estimated glomerular filtration rate; SCr, serum 
creatinine. 
Univariate Cox analysis revealed that the only renal recovery criteria 
significantly linked to one-year mortality was reduction in SCr to < 1.5 times 
baseline SCr on postoperative day 10 (HR 0.32; 95% CI: 0.17‒0.63) (Table 
XVII). 
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Table XVII: Univariate Cox analysis of all patients diagnosed with AKI, to compare the 
relationship between long-term mortality and the different criteria for renal recovery. 
Variable HR (95% CI) p-value 
SCr < 1.5 × baseline SCr   
            10 days 0.32 (0.17‒0.63) < 0.001 
            20 days 0.48 (0.21‒1.08) 0.075 
            30 days 0.50 (0.21‒1.20) 0.122 
SCr < 1.25 × baseline SCr   
            10 days 0.84 (0.46‒1.53) 0.582 
            20 days 1.28 (0.61‒2.68) 0.51 
            30 days 1.34 (0.62‒2.89) 0.461 
SCr < 1.1 × baseline SCr   
            10 days 0.96 (0.55‒1.68)                                                                                                                                    0.878
            20 days 1.32 (0.71‒2.45) 0.381 
            30 days 1.51 (0.79‒2.86) 0.212 
Recovering eGFR > 60 mL/min/1.73 m
2
   
            10 days 0.24 (0.07‒0.85) 0.027 
            20 days 0.33 (0.08‒1.47) 0.147 
            30 days 0.33 (0.08‒1.47) 0.205 
Recovering preoperative CKD category   
            10 days 0.53 (0.24‒1.15) 0.107 
            20 days 1.03 (0.36‒3.00) 0.954 
            30 days 1.12 (0.33‒3.75) 0.854 
CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; SCr, serum 
creatinine. 
4.4.2  Renal recovery 
The recovery rates are presented graphically in Figure 21. Renal recovery at 
10 days decreased in line with the severity of the initial AKI stage (98.1%, 
88.2%, and 64% for AKI stages 1, 2, and 3, respectively; p < 0.001).  
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Figure 21. Renal recovery rates for patients in study IV shown according to the initial 
stage of postoperative AKI. Renal recovery was defined as reaching SCr ratio < 1.5 ×  
baseline SCr. 
A comparison of the group that had recovered renal function and the 
group that did not is given in Table XVIII. Patients who had recovered renal 
function following AKI had significantly higher eGFR before surgery (61 vs. 
50 mL/min/1.73 m
2
; p < 0.001), but they were less likely to have undergone 
emergency surgery than the group that did not recover renal function. No 
significant difference was observed between the groups regarding 
preoperative risk assessment scores, hypertension, DM, neoplasms, age, or 
gender. 
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Table XVIII: Comparison of preoperative and intraoperative characteristics of patients 
who did and did not recover renal function (defined as reaching SCr ratio < 1.5 × 
baseline SCr on postoperative day 10). 
Variable Renal recovery 
N = 265 
No recovery 
N = 62 
p-value 
Patient-related 
factors 
   
Age, years 74 (67‒80) 74 (68‒80) 0.471 
Gender (male) 192 (72.5) 46 (74.2) 0.906 
Baseline SCr 99 (82‒117) 118 (94‒134) < 0.001 
Preoperative eGFR  61 (48.8‒78.6) 50.4 (42.2‒58.6) < 0.001 
> 90 21 (8.0) 3 (4.8) < 0.001 
60‒89 120 (45.8) 11 (17.7)  
30‒59 105 (40.0) 43 (69.4)  
15‒29 14 (5.3) 5 (8.1)  
< 15 2 (0.8) 0 (0)  
Hypertension  86 (32.5) 26 (41.9) 0.205 
Congestive heart 
failure 
67 (25.3) 16 (25.8) 1 
Ischemic heart 
disease 
190 (71.7) 45 (72.6) 1 
COPD 11 (4.2) 2 (3.2) 1 
Diabetes mellitus 43 (16.2) 12 (19.4) 0.686 
Liver disease 5 (1.9) 0 (0) 0.607 
Neoplasm 48 (18.1) 17 (27.4) 0.140 
ASA classification:    
1 0 (0) 0 (0) NA 
2 2 (0.8) 0 (0)  
3 139 (56.3) 23 (41.1)  
4 92 (37.2) 27 (48.2)  
5 14 (5.7) 6 (10.7)  
Surgery-related 
factors 
   
Emergency surgery 71 (26.8) 29 (46.8) 0.004 
Length of surgery, 
min 
241 (174‒305) 222 (132‒344) 0.339 
Length of hospital 
stay, days 
14 (10‒20) 12 (4‒34) 0.523 
Data are presented as median (interquartile range) for continuous variables and 
number (percentage) for categorical variables. 
AKI, acute kidney injury; ASA, American Society of Anesthesiologists physical status 
classification system; COPD, chronic obstructive pulmonary disease; eGFR, 
estimated glomerular filtration rate in mL/min/1.73 m
2
; SCr, serum creatinine. 
4.4.3  Survival 
Median follow-up time in AKI patients was 38.9 months (interquartile range: 
16.5‒78.7). Univariate logistic regression analysis showed independent risk 
factors for one-year mortality to be AKI stage 2 (unadjusted OR 3.59; 95% CI: 
1.64‒7.63; p = 0.001), ischemic heart disease (unadjusted OR 0.49; 95% CI: 
0.25‒0.96; p = 0.0342), preoperative kidney dysfunction (defined as eGFR < 
Results 
65 
60 mL/min/1.73 m
2
) (unadjusted OR 6.96; 95% CI: 3.05‒18.81; p < 0.001), an 
ASA classification of 4/5 (unadjusted OR 3.59; 95% CI: 1.66‒8.44; p = 
0.0018), emergency surgery (unadjusted OR 3.46; 95% CI: 1.80‒6.74; p < 
0.001), reoperation (unadjusted OR 2.76; 95% CI: 1.42‒5.34; p = 0.0025), 
operative time longer than 100 min (unadjusted OR 0.28; 95% CI: 0.13‒0.62; 
p = 0.0012), and recovery of renal function (unadjusted OR 0.25; 95% CI: 
0.08‒0.85, p = 0.019). Multivariate logistic regression revealed that 
preoperative kidney dysfunction and chronic heart failure were independently 
associated with one-year mortality (Table XIX). 
Table XIX: Risk factors for reduced one-year survival after surgery (by multivariate 
logistic regression). Renal recovery was defined as reaching SCr ratio < 1.5 × 
baseline SCr on postoperative day 10. 
 Adjusted OR (95% CI) p-value 
Congestive heart failure 6.13 (1.47‒29.07) 0.015 
eGFR < 60 mL/min/1.73 m
2
 8.41 (1.44‒160.02) 0.050 
Ischemic heart disease 0.28 (0.07‒1.14) 0.071 
Neoplasm 0.26 (0.03‒1.14) 0.134 
ASA classification 4/5 3.87 (1.01‒19.49) 0.064 
Renal recovery 0.26 (0.06‒1.07) 0.058 
eGFR, estimated glomerular filtration rate. 
CHF, preoperative kidney dysfunction, AKI stage 2 and 3, and reoperation 
were all found to be significantly and negatively associated with long-term 
mortality in multivariate Cox proportional hazard analysis of risk factors for 
long-term mortality, as shown in Table XX. Renal recovery was found to be 
protective against long-term mortality (HR 0.5), but the effect did not prove to 
be significant in multivariate analysis (p = 0.071). 
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Table XX: Multivariate Cox proportional hazard analysis of risk factors of long-term 
mortality. Renal recovery was defined as reaching SCr ratio < 1.5 × baseline SCr on 
postoperative day 10. 
 Adjusted HR (95% CI) p-value 
Preoperative factors   
Congestive heart failure 1.89 (1.03‒3.45) 0.039 
Advanged age (per year) 1.03 (0.99‒1.07) 0.163 
eGFR < 60 mL/min/1.73 m
2
 2.40 (1.26‒4.55) 0.008 
Postoperative factors   
AKI stage 1 1  
stage 2 3.44 (1.71‒6.91) < 0.001 
stage 3 2.89 (1.09‒7.74) 0.034 
Reoperation for bleeding  2.22 (1.17‒4.20) 0.014 
Renal recovery 0.50 (0.24‒1.06) 0.071 
eGFR, estimated glomerular filtration rate. 
Propensity score matching with a patient who did not recover renal 
function was achieved for 43 pairs of patients. PSM matching analysis 
showed that long-term survival of the group that reached renal recovery was 
significantly higher than in the group that did not, with a five-year survival of  
76.3% as compared to 65.6% (p = 0.04) (Figure 22). 
 
 
Figure 22. Comparison of long-term survival of individuals who achieved renal 
recovery (SCr < 1.5 × baseline SCr within 10 days from surgery) and a propensity 
score-matched control group of individuals who did not recover renal function. 
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4.5 Study V – Postoperative atrial fibrillation 
In the whole study population, the incidence of POAF was 44% (326 of 744). 
Annual incidence ranged from 36% to 52%, but the difference was found to 
be insignificant in Poisson regression analysis (p = 0.08) The incidence was 
significantly higher following CABG as compared to OPCAB, and following 
AVR or combined surgery as compared to isolated CABG. Table XXI shows 
a comparison of baseline characteristics of the group diagnosed with POAF 
and those with SR following surgery. Patients who experienced POAF were 
on average older and more likely to be female, compared to the group with 
SR. The extent of coronary artery sclerosis was less in the POAF group than 
in the SR group, but the former group had lower LVEF and higher 
preoperative risk assessment scores. No significant difference was seen 
regarding preoperative use of β- or Ca
2+
 blockers. 
Table XXI: Comparison of baseline characteristics in study V, between the group with 
sinus rhythm (SR) and the group with postoperative atrial fibrillation (POAF). Unless 
otherwise stated, mean and standard deviation is given for continuous variables and 
percentages are given in parentheses. 
 
POAF 
n = 326 
SR 
n = 418 
p-value 
Male 244 (74) 349 (83) 0.005 
Age, years 70 ± 9 64 ± 9 < 0.001 
DM 62 (19) 60 (14) 0.11 
HTN 213 (65) 248 (59) 0.11 
Dyslipidemia 161 (49) 263 (63) < 0.001 
Smoker 58 (18) 111 (35) 0.005 
CHF 66 (20) 35 (8) < 0.001 
No. of affected coronary arteries 2 3 < 0.001 
LVEF, % 51 55 < 0.001 
Standard EuroSCORE 6 4 < 0.001 
Preoperative β-blocker use 201 (62) 291 (70) 0.074 
Preoperative Ca
2+
-blocker use 67 (21) 80 (19) 0.58 
Preoperative statin use 201 (63) 316 (76) < 0.001 
AVR, atrial valve replacement; CHF, congestive heart failure; DM, diabetes mellitus; 
HTN, hypertension; LVEF, left ventricular ejection fraction. 
4.5.1  Postoperative complications and survival 
Table XXII gives an overview of the postoperative complications. Chest tube 
output in the first 24 h and RBC transfusion rates were significantly higher in 
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the POAF group, as was the incidence of deep surgical wound infections and 
MOF. Furthermore, length of total hospital stay and ICU stay was higher: 
three and five times more, respectively (p < 0.001). Finally, operative 
mortality was about sevenfold higher in the POAF group than in the SR 
group. 
Table XXII: Intraoperative characteristics of patients in study V, and postoperative 
complications. Comparison of the group with sinus rhythm (SR) and postoperative 
atrial fibrillation (POAF). Unless otherwise stated, mean and standard deviation is 
given for continuous variables and percentages are given in parentheses. 
 
POAF 
n = 326 
 SR 
n = 418 
p-value 
Bleeding in first 24 h, mL, mean 
(range) 
850 (120‒
4,980) 
 773 (120‒
31,820) 
< 0.001 
CABG/OPCAB 233 (37)  391 (63) < 0.001 
OPCAB 270 (46)  313 (54) 0.01 
AVR 42 (73)  15 (27) < 0.001 
AVR + CABG 51 (81)  12 (19) < 0.001 
Skin-to-skin time, min, (range) 
205 (90‒
640) 
 
200 (100‒555) < 0.001 
CPB time, min, (range) 95 (38‒366)  80 (28‒265) < 0.001 
Aortic clamp time, min, (range) 49 (19‒209)  40 (13‒204) < 0.001 
Sternum dehiscence 15 (5.0)  3 (0.7) 0.24 
MOF/ARDS 25 (8.0)  1 (0.2) < 0.001 
Reoperation due to bleeding 14 (4)  20 (5) 0.88 
Pneumonia 34 (10)  16 (4) < 0.001 
Superficial surgical wound 
infection 
31 (10) 
 
36 (9) 0.66 
UTI 26 (8)  11 (3) 0.002 
Total hospital stay, days, mean 
(range) 
15 (1‒110) 
 
10 (1‒47) < 0.001 
ICU stay, days, mean (range) 3 (1‒13)  1 (1‒41) < 0.001 
≤ 30 day operative mortality 15 (5)  3 (1) 0.001 
AKI, acute kidney injury; ARDS, acute respiratory distress syndrome; AVR, atrial 
valve replacement; CABG, coronary artery bypass grafting; CPB, cardiopulmonary 
bypass; ICU, intensive care unit; MI, myocardial infarction; MOF, multiple organ 
failure; OPCAB, off-pump coronary artery bypass; UTI, urinary tract infection. 
  
Results 
69 
Long-term survival of patients who suffered POAF was significantly less 
than in the group with SR. One-year survival for the POAF and SR groups 
was found to be 92% versus 98% (p < 0.001). Similarly, five-year survival 
was 85% versus 93% (p < 0.001), respectively. 
The survival of patients in study V is shown in Figure 23. When corrected 
for age, emergency operation, AVR, and standard EuroSCORE in the final 
regression analysis model, POAF was found to be an independent predictor 
of mortality (HR 2.63; 95% CI: 1.76‒3.93, p < 0.001). 
Figure 23. A Kaplan-Meier survival curve comparing patients with postoperative atrial 
fibrillation (POAF) and normal sinus rhythm (NSR) following CABG/OPCAB or AVR ± 
CABG in Iceland, 2002‒2006. 
4.5.2  Risk factors for POAF, and probability assessment 
Multivariable logistic regression analysis revealed that the strongest 
independent risk factors for POAF were AVR, CHF, standard EuroSCORE, 
and advanced age  (Table XXIII). 
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Table XXIII: Independent risk factors for POAF in study V 
 OR (95% CI) p-value 
Aortic valve replacement 4.36 (2.68‒7.07) < 0.001 
Congestive heart failure 1.81 (1.10‒2.99) < 0.001 
Standard EuroSCORE (per point) 1.10 (1.03‒1.17) < 0.001 
Age (per year) 1.05 (1.03‒1.07) < 0.001 
Lastly, a risk score based on standard EuroSCORE, age, and type of 
surgery, was created to predict the probability of POAF following 
CABG/OPCAB or AVR+CABG for patients without any previous history of 
AFib (Table XXIV). 
Table XXIV: Probability chart for POAF in study V. A risk score is given to evaluate 
the probability (in %) of POAF following CABG/OPCAB or AVR ± CABG for patients 
with no previous history of atrial fibrillation. 
Isolated CABG/OPCAB 
 EuroSCORE 
Age 0 2 4 6 8 10    
50 14 17 20 24 29 34    
55 17 20 24 29 34 39    
60 20 24 29 34 39 44    
65 24 29 34 39 44 50    
70 29 34 39 45 50 56    
75 34 39 45 50 56 61    
80 39 45 50 56 61 67    
         < 30% 
AVR ± CABG   30‒70% 
 EuroSCORE   > 70% 
Age 2 4 6 8 10     
50 47 53 58 64 69     
55 53 59 64 69 74     
60 59 64 69 74 78     
65 64 69 74 78 82     
70 69 74 78 82 85     
75 74 78 82 85 87     
80 78 82 88 88 90     
AVR, aortic valve replacement; CABG, coronary artery bypass grafting; OPCAB, off- 
pump coronary artery bypass. 
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5 Discussion 
In this thesis, the association between AKI and adverse patient outcomes has 
been elucidated, in both the short term and the long term. Although a causal 
relationship cannot be definitely established in retrospective studies, AKI was 
found to be significantly associated with less favorable outcome following 
myocardial revascularization surgery and also AVR. This was mainly seen in 
higher rates of complications and worse survival in patients who experienced 
AKI. The same held true for patients who experienced POAF. Importantly, the 
finding that kidney dysfunction negatively affects patient outcome is in line 
with the finding that recovery of renal function was associated with better 
postoperative outcome regarding long-term survival. 
5.1.1 Study I – Identification of baseline kidney function in AKI 
studies 
A major point of criticism of the RIFLE criteria is the requirement for baseline 
SCr values, which are often missing in the clinical setting. The RIFLE criteria 
recommend assumption that baseline eGFR is 75 mL/min/m
2
, when there is 
no history of CKD, and back-calculation of SCr using the MDRD equation, 
which in many cases appears to be too rough an approximation (Bagshaw et 
al., 2009; Pickering & Endre, 2010). Previous studies on the incidence of 
ICU-associated AKI have found variable rates of AKI ranging from 20% to 
80% (Crowley & Peixoto, 2009; Hoste et al., 2006; Medve et al., 2011; 
Ostermann & Chang, 2007). This is believed to be in part due to the fact that 
assuming a normal baseline SCr value in the ICU population overestimates 
the incidence of AKI, whereas using the lowest SCr measured during ICU 
admission is likely to lead to underestimation of AKI. This was supported by a 
recent study that showed an overestimation of incidence of AKI of 11% when 
using back-calculation of SCr with the MDRD equation, as compared to 
documented baseline SCr (Pickering & Endre, 2010). Before embarking on 
further research on the subject of AKI, we therefore set out to evaluate the 
importance of thorough identification of baseline kidney function, as opposed 
to ascertaining incidence based on back-calculations. Indeed in this study, 
the use of estimated instead of measured baseline SCr led to a relative 
overestimation of AKI by 16% (absolute overestimation: 3.5%). 
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After meticulous identification of baseline SCr, the incidence of AKI in 
adults admitted to the ICU was found to be almost 22%, with equal 
distribution between the three RIFLE outcome classes. 
In line with studies II and III in the thesis, patients who experienced AKI 
were more likely to have adverse outcomes, and hospital mortality was four 
times higher than in the patients who did not have AKI. Furthermore, 1-year 
survival was significantly less. However, during the three years of follow-up, 
only three patients required long-term RRT. 
Research in the field of AKI took great strides following the publication of 
consensus criteria for AKI. However, contemporary studies are still often 
impeded by insufficient data on baseline SCr. What is more, as previously 
discussed, research is hindered by the inherent flaws of SCr in the detection 
of acute changes in kidney function. Thus, the search for biomarkers more 
sensitive in the recognition of AKI is ongoing. In the work included in this 
thesis, we based our need for rigorous identification of baseline SCr on the 
results of study I, namely a relative overestimation of AKI incidence of 16% 
when using back-calculation methods.  
5.1.2  Study II – AKI following CABG 
Owing to comprehensive nationwide registries, SCr could be identified in 
98% of the patient cohort in study II, thus permitting reliable identification of 
postoperative AKI. Furthermore, study II showed that roughly 10% of patients 
had postoperative AKI, which is in the lower range compared to most 
previous studies on patients who undergo CABG (Machado et al., 2009; 
Parolari et al., 2012). 
Worldwide, the incidence of AKI has been increasing (Hsu, 2010). 
Underlying reasons might be changes in the characteristics of hospitalized 
patients (e.g. greater comorbidity, higher severity of illness scores, and 
higher age), the advent of more complex interventions, and prolongation of 
life support (Bellomo, 2006). However, in this study an overall decreasing 
incidence of AKI over time was observed. The reasons for this are not 
obvious, but they might have to do with improved perioperative care or 
increased awareness of AKI following the publication of the RIFLE criteria. 
However, factors such as the increasing use of lung-protective ventilation 
(Koyner & Murray, 2010), and focus on optimal peri- and postoperative fluid 
balance, may play a role (Payen et al., 2008; Prowle et al., 2014). 
Development of AKI in general may also be significantly influenced by delays 
in adequate treatment of infections, as shown in a 2010 study―in which 
delays in the treatment of sepsis resulted in a 3.4% increase in SCr per hour 
(Kiers et al., 2010). 
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In study II, independent risk factors for AKI were higher BMI, DM, lower 
preoperative eGFR, higher EuroSCORE, reoperation due to bleeding, and 
higher numbers of RBC transfusions. The common physiological pathway 
behind these risk factors may be related to the kidney’s sensitivity to non-
pulsatile and reduced blood flow, especially in cases of preceding renal 
dysfunction (Bellomo et al., 2004; Mao et al., 2013). Hypertensive patients 
are generally more dependent on blood pressure to drive kidney perfusion, 
and suboptimal conditions such as emergency surgery and the intraoperative 
need for inotropes are known to affect tissue perfusion (Brenner, 2005). 
The most common postoperative complication following CABG was POAF 
(diagnosed in 39% of patients). Moreover, the incidence of POAF was found 
to be significantly higher in the AKI group than in those who did not sustain 
AKI (53 vs. 38%; p = 0.001). Previous studies have indicated a similar 
relationship between decrease in kidney function and increased risk of POAF 
(Barbosa et al., 2011). A recent prospective study in which AKI was found to 
be an independent risk factor for development of POAF after cardiac surgery 
further supports this (Ng et al., 2016). The total incidence of AKI and POAF in 
the study was 30% and 17%, respectively. However, patients who developed 
AKI had a rate of POAF of 28%, and had twice the risk of developing POAF 
(RR 1.7; 95% CI: 1.43‒2.01; p  <  0.001) (Ng et al., 2016). 
In study II, AKI was found to be an independent risk factor for incident 
CKD, but not ESRD. Furthermore, patients who developed AKI were likelier 
to experience postoperative complications and had a higher 30-day mortality. 
Importantly, long-term survival was inversely correlated to severity of AKI, 
even though the vast majority of patients had recovered kidney function 
(defined as a reduction in SCr to < 1.25 times baseline SCr). However, when 
the model for risk factors of long-term survival was corrected for interaction 
between AKI and POAF, only POAF was found to be a significant risk factor 
for 30-day mortality, possibly indicating a detrimental role of POAF in patient 
outcome. 
At postoperative day 10, renal recovery rates were 96%, 78%, and 94% 
for AKI stages 1, 2, and 3, respectively. By day 20, rates for recovery of 
patients classified as stage 2 had risen further to 96%. Comparison of studies 
reporting renal recovery is, however, not straightforward―as highly variable 
definitions have been used. Even so, in line with various studies, our results 
showed that patients with recovered renal function had a higher probability of 
long-term survival than those who did not (Pannu et al., 2013; Swaminathan 
et al., 2010).  
5.1.3  Study III – AKI following AVR 
This study further demonstrated the substantial risk of acquiring AKI after 
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open-heart surgery, as well as the association between AKI and adverse 
postoperative outcomes and increased 30-day mortality. However, it is 
noteworthy that AKI was not found to be significantly associated with long-
term survival, but type-II error cannot be excluded. 
As compared to patients who underwent isolated CABG, patients who 
underwent AVR had an increased risk of AKI. In addition, they more often 
had reduced preoperative eGFR, they were 4 years older on average, and 
they generally underwent longer and more complex surgery, which may all 
lead to an increased risk of AKI. 
In line with previous research, obesity, prolonged CPB time, and a higher 
number of RBC transfusions were independent risk factors for AKI. 
Interestingly, even in healthy populations, obesity has been linked to 
increased risk of renal failure (Chang et al., 2016). Prolonged CPB time is 
also a previously well described risk factor for AKI in cardiac surgery patients, 
but the underlying pathophysiology is complex. However, reduced perfusion 
pressure, lower oxygen tension in the renal parenchyma, erythrocyte 
hemolysis, alterations in regional kidney blood flow due to non-pulsatile CPB 
flow, and induction of the systemic inflammatory response, caused by contact 
with the artificial surface of the CPB circuit, are believed to have key roles 
(Ascione & Angelini, 2003; Okusa, 2002). 
Observational studies with similar design to that of study II have shown 
that transfusion of RBCs is independently associated with AKI (Karkouti et 
al., 2009). In Iceland, transfusion rates are appreciably higher after AVR than 
after CABG, as seen in studies II and III in this thesis. The transfusion rates 
are indeed high compared to transfusions of comparable populations 
undergoing AVR in neighboring countries (Ternstrom et al., 2014). This 
relationship between transfusions and AKI, which was also observed in study 
II, remained significant even after correction in the logistic regression model 
for preoperative anemia, perioperative bleeding, and reoperation for bleeding. 
Notably, studies have indicated that storage of RBCs might induce structural 
changes to erythrocytes, impairing oxygen delivery capacity and predisposing 
to hemolysis (Karkouti, 2012; Tinmouth et al., 2006). The increased 
concentrations of free erythrocyte constituents, such as iron and hemoglobin, 
can subsequently exhaust physiological scavenger systems (i.e. transferrin 
and haptoglobin), exacerbate oxidative stress to tissues, and even lead to 
tissue damage (Okusa, 2002). However, a recent prospective study 
underscored the fact that a causal relationship cannot be assumed in 
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observational studies, and both higher transfusion rates and increased risk of 
AKI may be due other comorbidities (Murphy et al., 2015). 
As in study II, POAF was the most common postoperative complication 
after AVR; it was diagnosed in 68% of patients, which is in line with other 
studies on patients who have undergone AVR (Maisel et al., 2001). This 
complication was diagnosed in 78% of patients in the AKI group as opposed 
to 65% of non-AKI patients, but this difference was not significant.  
Only 4% of patients required RRT following surgery, which is a low rate 
compared to various other studies (Hobson et al., 2009; Lawman et al., 
2002). Of the 15 patients who needed RRT, three went on to fulfill criteria for 
diagnoses of RIFLE classification L. Ultimately, the one patient who 
progressed to RIFLE classification E was free of dialysis after 108 days. AKI 
was, however, associated with other adverse postoperative outcomes in 
addition to operative mortality. Furthermore, long-term survival was lower in 
the group that experienced AKI, even though AKI was not found to be 
independently associated with long-term survival. This contrasts with the 
results of various other studies, which have shown a relationship between 
AKI and both short-term and long-term survival (Hobson et al., 2009; Hoste et 
al., 2006; Lafrance & Miller, 2010). However, when AVR and AVR + CABG 
patients were analyzed separately, a significant relationship was found 
between long-term survival and AKI in those who underwent combined 
surgery. This finding might be explained by confounding effects of other 
underlying risk factors. The sub-population of patients who underwent both 
AVR and CABG is likely to have had a different comorbidity profile, mainly 
regarding risk factors for coronary atherosclerosis. In turn, atherosclerosis 
affects both the risk of AKI and death (Lekawanvijit & Krum, 2014). 
5.1.4  Study IV - The importance of renal recovery following AKI 
The main focus of this study was renal recovery following AKI and how it 
affects long-term outcome in patients. The results of study IV indicate that 
patients who develop AKI fare better if they subsequently recover their kidney 
function. This might suggest that AKI after cardiac surgery is not only a 
marker of worse patient status, but in itself associated with adverse outcome. 
The main finding in study IV was that by postoperative day 10, 52‒95% of 
patients had recovered their renal function following AKI, depending on the 
definition used. However, in our study, we did not find any criteria for renal 
recovery that were sufficiently associated with survival to predict a causative 
relationship. This might be due to the stronger effect of other variables on 
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one-year mortality, such as worse preoperative state and emergency surgery. 
Nevertheless, a favorable relationship was found between renal recovery, 
defined as recovery to within 1.5 times baseline SCr by postoperative day 10, 
and one-year survival. What is more, five-year survival was almost 11% 
higher than in a propensity score-matched group of patients who did not have 
recovery of renal function. 
Previous studies have shown that kidney function following AKI may be 
highly variable, with periods of recovery and deterioration at inconstant rates 
(Schiffl & Fischer, 2008). These studies have also highlighted that a kidney 
insult compounding previously developed AKI significantly reduces the 
chances of complete renal recovery (Schiffl & Fischer, 2008). This has been 
confirmed in a 2016 study showing that relapse occurs in 37% of patients 
who have had renal recovery (defined according to the ADQI criteria 
(Bellomo et al., 2004)), most commonly in the first three days after the 
recovery (Kellum et al., 2016). Furthermore, both relapse and non-recovery 
of renal function were found to be associated with significantly higher one-
year mortality rates than in patients who had early recovery of renal function 
(31%, 60%, and 10%, respectively; p < 0.001) (Kellum et al., 2016). This 
shows a limitation of our study design, as postoperative SCr was measured 
prospectively, thereby reducing our ability to reliably identify relapse in kidney 
function after renal recovery. However, rates of renal recovery were higher in 
study IV than in the previously mentioned study (86% as compared to 60%). 
This may be largely explained by the differing study groups, i.e. inclusion of 
all patients who experienced first-time postoperative AKI in study IV as 
opposed to only stage 2‒3 AKI in critically ill patients in the comparison 
study. 
Ultimately, the results of study IV show the need for studies of long-term 
prognosis of AKI. As a systematic review from 2015 stressed, future AKI 
studies should reliably report both pre-AKI kidney function and post-AKI 
kidney function at fixed follow-up points (Sawhney et al., 2015). 
5.1.5  Study V – POAF, the most common complication of heart 
surgery 
In studies II and III, POAF was found to be the most common postoperative 
complication after open-heart surgery. Like AKI, POAF is a common and 
potentially serious complication of cardiac surgery. The incidence of POAF 
was found to be high in our cohort, occurring in 44% of cases as opposed to 
the 20‒30% reported in most other observational studies (Andrews et al., 
1991; Creswell et al., 1993; Echahidi et al., 2008). A hypothesis of this study 
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was that one of the reasons for the high incidence might be the limited 
systematic use of prophylactic treatment, such as β- and calcium channel-
blockers, during the study period, as well as dietary and genetic factors 
(Arnar et al., 2016; Stefansdottir et al., 2011). 
As in studies II and III, study V showed that patients who experienced 
POAF also had significantly higher RBC transfusion rates. This might be due 
to the fact that patients who experience POAF, and thereby have decreased 
cardiac output, are possibly more sensitive to the effects of perioperative 
anemia (Ng et al., 2016). However, as previously mentioned, transfusion of 
RBCs leads to a pro-inflammatory response, thereby possibly predisposing to 
both POAF and AKI (Bruins et al., 1997; Fried et al., 2004; Shlipak et al., 
2003). However, causality cannot be confirmed, and, all these outcomes may 
indeed be markers of an increased pathophysiological burden of a patient. 
Independent risk factors for POAF were advanced age, the complexity of 
the surgical procedure, a history of CHF, a low ejection fraction, and a higher 
EuroSCORE. These factors have also been reported as independent risk 
factors for AKI―and it could be conjectured that POAF and AKI might share 
underlying pathophysiological mechanisms, e.g. the activation of the 
systematic inflammatory response (Albahrani et al., 2003; Creswell, 1999; Ng 
et al., 2016). When AKI occurs, pro-inflammatory cytokine clearance is 
decreased and oxidative stress is increased (Friedrichs et al., 2011). In turn, 
reactive oxygen species and inflammatory markers have been found to affect 
the function of cell ion channels and gap junctions, thereby affecting cellular 
electrical stability and conduction of impulses, which are necessary for the 
proper function of the atrial myocytes (Friedrichs et al., 2011). In line with 
this, the incidence of both POAF and AKI peaks at postoperative days 2‒3 
and coincides with peak levels of inflammatory markers (Chung et al., 2001; 
Ng et al., 2016). 
Various studies have shown that both POAF and AKI negatively affect 
long-term survival (El-Chami et al., 2010). Causality can, however, be difficult 
to determine, as studies are mostly retrospective. In studies II and V, we did 
not find a significant interaction between AKI and POAF regarding 
association with long-term survival. Both were, however, found to have a 
negative effect on survival. 
5.2 Strengths and limitations 
This thesis is based on five retrospective observational cohort studies. There 
is therefore an inherent risk of shortcomings, mainly the distorting effect of 
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unrecognized confounding factors and bias. However, it has been shown that 
well-designed observational studies will not necessarily systematically 
overestimate the association between exposure and outcome when 
compared to the gold standard of evidence-based medicine, i.e. randomized 
controlled trials (RCTs) (Benson & Hartz, 2000; Concato et al., 2000). What 
is more, observational studies usually carry the additional advantage of lower 
cost and a broader range of patient population. In the case of the 
epidemiology of AKI, RCTs might even be impossible or unethical, so 
observational studies may be better suited to the task. 
The chance of misclassification cannot be excluded in our studies. As is 
often the case in retrospective studies on AKI, there was no comprehensive 
registration of urine output in our datasets. The diagnosis of AKI was 
therefore solely based on the SCr component of the RIFLE and KDIGO 
criteria. This might lead to underestimation of the incidence of AKI, but 
studies have shown that patients diagnosed with AKI based on urine output 
usually have milder disease and survival rates comparable to those in 
patients without AKI (Kellum et al., 2015). The RIFLE and KDIGO criteria for 
the classification of AKI are based on functional markers of kidney injury 
(namely SCr) rather than direct histological evidence of renal tissue 
pathology or biomarkers of injury. Furthermore, patients may be incorrectly 
diagnosed as having or not having AKI in cases where baseline SCr is 
missing. Indeed, as already pointed out, a major point of criticism regarding 
the use of the RIFLE, AKIN, and KDIGO criteria in observational studies is 
the sometimes unreliable documentation of baseline SCr in clinical practice 
(Pickering & Endre, 2010). It has even been shown that back-calculation of 
baseline SCr, as proposed in the RIFLE criteria, can lead to misclassification 
of AKI (Pickering & Endre, 2010). This was highlighted further in the findings 
of study I, which showed overestimation of the incidence of AKI in the ICU 
when baseline SCr was calculated from a presumed normal eGFR. In study 
II, baseline SCr was available for approximately 98% of the population and 
the 44 patients missing baseline SCr were excluded from the study. In study 
III baseline SCr was missing in 15 patients (4% of the cohort), and in those 
cases the mean baseline SCr of the cohort was used instead.  
In all five studies included in this thesis, multivariate regression analysis 
was used in an attempt to correct for confounding factors. Data on numerous 
variables were registered for every patient in the study, and the databases 
used were continuously updated during the research period. However, as 
with all retrospective studies, registration of clinical variables is not all-
encompassing and is sensitive to under-reporting, e.g. patients’ non-
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disclosure of true smoking status. Based on our studies, we cannot 
determine whether AKI has a direct causal relationship with the outcomes 
measured. It might be that AKI is a surrogate marker of worse overall status 
of patients who are prone to adverse outcomes rather than being a direct 
cause of worse prognosis. However, RCTs to measure the true effect of AKI 
on patients would likely unachievable and ethically questionable.  
Lastly, the risk model presented in study V has not been validated in 
prospective studies, and the risk of overfitting cannot be excluded. 
Essentially, this means that our risk model might describe a random error 
rather than an underlying relationship between POAF and risk factors used to 
construct the model. However, the model was constructed using only three 
risk factors, which to some extent limits the probability of overfitting. 
Furthermore, we believe that the simplicity of the model might possibly aid in 
its possible future clinical application. 
A major strength of the studies included in the thesis is their nationwide 
nature. The Icelandic nation can in most respects be considered to be similar 
to other western countries with regard to age, sex distribution, and 
comorbidities―leading to wide generalizability of our results to countries with 
similar levels of healthcare. Furthermore, in Iceland all patients are assigned 
a unique personal identification number, allowing consistency in gathering of 
individual patient data. Data are collected into centralized nationwide 
registers, permitting thorough analysis. Also, the small size of the nation, with 
negligible migration, permits extremely comprehensive long-term follow-up 
regarding morbidity and mortality. Importantly, we were able to cross-
reference three separate databases to ensure that patients were reliably 
registered in our studies. Furthermore, in study II we were able to collect 
long-term follow-up SCr values in the majority of patients who had AKI, 
thereby facilitating diagnosis and analysis of recovery of renal function. In 
addition, we were able to follow up long-term need for RRT in all patients with 
the help of the Icelandic End-Stage Renal Disease Registry, which 
comprehensively registers data on all patients who undergo RRT for CKD in 
Iceland. 
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6 Conclusions and future studies 
AKI is a serious complication in various clinical settings and is associated 
with adverse outcomes, such as increased hospital stay and ICU stay, higher 
complication rates, and higher mortality. Despite advances in assessment 
and treatment of the complications of AKI (e.g. fluid overload and electrolyte 
disturbances), with measures ranging from increased hydration to 
hemodialysis, AKI is still a costly condition and these patients are still found 
to fare worse later on. Furthermore, recovery of renal function is significantly 
associated with better outcome in patients who have suffered postoperative 
AKI.  
We were unable to show any significant interaction between AKI and 
another common complication of cardiac surgery, POAF, although both were 
significantly correlated to worse survival. Indeed, based on our studies a 
causal relationship cannot be shown between AKI and POAF and other 
adverse outcomes. AKI and POAF, which are both more likely in states of 
inflammation, may be markers of more severe illness rather than being 
directly causative factors of worse prognosis. 
However, our results further highlight the need to concentrate on the 
population prone to AKI and POAF. Research on the subject remains 
important for elucidation of possible, as yet unknown, risk factors and links 
between AKI and POAF and other complications in the postoperative period.  
Epidemiological studies are valuable, as they provide insight into 
potentially modifiable risk factors. However, in the case of AKI, clinical 
research was for a long time impeded by the lack of consensus criteria. 
Despite the strides that were taken following the publication of the RIFLE 
criteria, studies on AKI are still marred by the inherent flaw of basing the 
definition on SCr. Ideally, a biomarker for acute kidney injury should be 
kidney-specific, site-specific (to aid in differentiation of pre-renal, intrinsic, and 
post-renal causes), detectable early in the process of tissue injury, and 
inexpensive and reliably measurable. To date, no such marker exists. Studies 
have yielded biomarkers such as NGAL and KIM-1. They have not, however, 
been validated extensively and it is still important to continue this research. 
Future studies might also try to identify factors that could affect recovery 
of renal function. Before that, however, a consensus must be reached as to 
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what constitutes renal recovery. This might be achieved in a large 
prospective observational study in which patients who experience AKI would 
have closer monitoring of kidney function at predefined time intervals as well 
as long-term follow-up. 
Unfortunately, except for RRT, there are no supportive measures for 
patients with AKI. Thus, up until now treatment has been directed at avoiding 
further injury of the kidney through goal-directed resuscitation and avoidance 
of nephrotoxic drugs whenever possible. Ideally, the perfect study would help 
in identification of measures that would be applicable in both prevention and 
treatment of this serious complication.  
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